ГИДРОФИЛЬНЫЕ БИОЛОГИЧЕСКИ СОВМЕСТИМЫЕ АДГЕЗИВНЫЕ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ

Изобретение относится к применению гидрофильных, биологически совместимых адгезивов в системах доставки лекарственных средств, в повязках для ран, в биоэлектродах и в других системах, в которых гидрофильные, биологически совместимые адгезивы являются желательными. В частности, изобретение относится к набухающим в воде, не растворимым в воде полимерам, которые в комбинации делают композицию липкой при контакте с влагой, в которой первый набухающий в воде водонерастворимый полимер является катионным, второй набухающий в воде водонерастворимый полимер является анионным и полимеры связаны ионными связями друг с другом с образованием полимерного матрикса. Гидрофильные, биологически совместимые адгезивы приклеиваются к поверхности тела при сохранении их когезионной способности. 5 н. и 19 з.п. ф-лы, 1 ил.

АДГЕЗИВНЫЕ КОМПЛЕКСНЫЕ КОАЦЕРВАТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Изобретение относится к области биоадгезивов и представляет собой адгезивный комплексный коацерват или полиэлектролитный комплекс, содержащий, по меньшей мере, один поликатион, который содержит положительно заряженный белок, продуцируемый P. Californica, или полимер, содержащий, по меньшей мере, один фрагмент формулы I, по меньшей мере, один полианион, который содержит полифосфатное соединение, полифосфосерин или полимер, содержащий, по меньшей мере, один фрагмент формулы II, и, по меньшей мере, один многовалентный катион, при этом, по меньшей мере, один поликатион или полианион представляет собой синтетическое соединение и поликатион содержит, по меньшей мере, одну кросс-сшивающую группу и/или полианион содержит, по меньшей мере, одну кросс-сшивающую группу, где указанные кросс-сшивающие группы способны к кросс-сшивке друг с другом. Изобретение обеспечивает получение адгезивных комплексных коацерватов, обладающих низким межфазным натяжением в воде и повышенной когезионной прочностью. 13 ...

ПОВЯЗКА С ПРОЛОНГИРОВАННЫМ ВЫДЕЛЕНИЕМ АКТИВНЫХ ВЕЩЕСТВ

Группа изобретений относится к медицине. Описаны повязки на основе полисульфатированных олигосахаридов, демонстрирующим пролонгированное выделение указанных активных веществ, а также способ их получения, причем способ включает этап обработки этиленоксидом. Изобретение относится к применению этих повязок для ухода за ранами и для лечения и/или предупреждения образования рубцов и растяжек кожи. Способом достигается более высокое выделение активных веществ. 5 н. и 11 з.п. ф-лы, 4 ил., 2 пр.

НОВОЕ АКТИВНОЕ ВЕЩЕСТВО ДЛЯ ЗАЖИВЛЕНИЯ И ЕГО ПРИМЕНЕНИЕ

Представлена группа изобретений, которые относятся к медицине, а именно к дерматологии. Группа изобретений включает в себя применение известного соединения в качестве агента для изготовления композиции, предназначенной для стимуляции и/или ускорения пролиферации фибробластов in vivo и ex vivo и, следовательно, заживления ран, а также повязку для лечения раны с этим соединением. Это соединение представляет собой сополимер соли 2-метил-2-[(1-оксо-2-пропенил)амино]-1-пропансульфоновой кислоты и 2-гидроксиэтилового эфира пропеновой кислоты. Его можно применять отдельно или в комбинации с другими активными веществами для индукции или ускорения заживления ран. Это соединение, отдельно или в комбинации с другим активным веществом, можно вводить непосредственно на рану и окружающую область или слизистые оболочки путем местного нанесения. Настоящие изобретения также находят применение для изготовления повязок, основанных на гидрогелях и на гидроколлоидах, в которые включают вышеупомянутый сополимер ...

ПЕПТИДНАЯ КОМПОЗИЦИЯ

Группа изобретений относится к области медицины, а именно к стабильной пептидной композиции, включающей: самособирающийся пептид; буферный агент, содержащий по меньшей мере одно вещество, выбранное из группы, состоящей из гистидина, нитрата тиамина, пиридина, бис-триса, этилендиамина и/или N-метилморфолина; и воду, при этом стабильная пептидная композиция имеет рН от 4,5 до 6,6; причем суммарный заряд аминокислотных остатков, содержащихся в самособирающемся пептиде, составляет между более 0 и +3 или менее в стабильной пептидной композиции; при этом С-конец самособирающегося пептида включает амидную группу; причем аминокислота на С-конце самособирающегося пептида включает основную аминокислоту; при этом самособирающийся пептид образован из следующей аминокислотной последовательности: a1b1c1b2a2b3db4a3b5c2b6a4, где каждый остаток a1-a4представляет собой основной аминокислотный остаток, каждый остаток b1-b6представляет собой незаряженный полярный аминокислотный остаток и/или гидрофобный аминокислотный ...

СПОСОБ, ПРОБИРКА И УСТРОЙСТВО ДЛЯ ПРИГОТОВЛЕНИЯ КОМПОЗИЦИИ ДЛЯ ЗАЖИВЛЕНИЯ РАН

... 1. Способ приготовления сыворотки с тромбином, включающий следующие стадии:a) забор цельной крови в пробирку, где указанная пробирка выбрана изi) пробирки, содержащей гель для отбора клеток, предпочтительно тиксотропный гель, и которая предпочтительно представляет собой стеклянную пробирку для отбора клеток, содержащую тиксотропный гель на основе полиэфира, илиii) пустой стеклянной пробирки для отбора клеток,где указанная пробирка необязательно дополнительно содержит активатор коагуляции, который предпочтительно представляет собой глюконат кальция,b) центрифугирование указанной пробирки до высвобождения сыворотки с тромбином иc) сбор указанной сыворотки с тромбином, иd) необязательно смешивание сывороткой с тромбином с активатором коагуляции, который предпочтительно представляет собой глюконат кальция,где указанная сыворотка с тромбином предпочтительно является аутологичной.2. Способ по п.1, отличающийся тем, что указанную пробирку подвергают центрифугированию при ускорении от около 1000g ...

ГИДРОФИЛЬНЫЕ БИОЛОГИЧЕСКИ СОВМЕСТИМЫЕ АДГЕЗИВНЫЕ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ

... 1. Фармацевтическая композиция, содержащая смесь: терапевтически эффективного количества активного агента и по меньшей мере двух набухающих в воде водонерастворимых полимеров, которые в комбинации делают композицию липкой при контакте с влагой, в которой первый набухающий в воде водонерастворимый полимер является катионным, второй набухающий в воде водонерастворимый полимер является анионным и полимеры ионно связаны друг с другом с образованием полимерного матрикса. 2. Фармацевтическая композиция по п. 1, в которой по меньшей мере один из набухающих в воде водонерастворимых полимеров представляет собой полимер на акрилатной основе. 3. Фармацевтическая композиция по п. 2, в которой полимер на акрилатной основе представляет собой полимер или сополимер акриловой кислоты, метакриловой кислоты, акрилата, метилакрилата, этилакрилата, метилметакрилата, этилметакрилата, диалкиламиноалкилакрилата, диалкиламиноалкилметакрилата, триалкиламмониоалкилакрилата и/или триалкиламмониоалкилметакрилата. 4 ...

КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЦЕЛЛЮЛОЗУ, РАСТИТЕЛЬНОЕ МАСЛО И ЛЕТУЧИЙ РАСТВОРИТЕЛЬ И ЕЕ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОВЯЗКИ

... 1. Жидкая композиция, предназначенная для нанесения на кожу, содержащая производное целлюлозы, растительное масло и летучий растворитель для указанного производного целлюлозы, характеризующаяся тем, что содержание производного целлюлозы составляет 6-13% масс. в пересчете на сухой остаток от общей массы композиции, содержание растительного масла составляет 5-15% масс. от общей массы композиции, а массовое отношение масло/целлюлоза в пересчете на сухой остаток составляет 0,8-1,5.2. Композиция по п.1, характеризующаяся тем, что производное целлюлозы является нитроцеллюлозой.3. Композиция по любому из пп.1 и 2, характеризующаяся тем, что растительное масло является касторовым маслом.4. Композиция по любому из пп.1 и 2, характеризующаяся тем, что содержание масла составляет 7-12% масс. от общей массы композиции.5. Композиция по любому из пп.1 и 2, характеризующаяся тем, что содержание растворителя указанного производного целлюлозы составляет 70-90% масс. от общей массы композиции.6. Композиция ...

СПОСОБ ПОЛУЧЕНИЯ СМЕСИ ДЛЯ РАСПЫЛЕНИЯ КЛЕТОК-ФИБРОБЛАСТОВ КЕРАТИНОЦИТОВ ЧЕЛОВЕКА В РАСТВОРЕ И ЕЕ ПРИМЕНЕНИЕ В КАЧЕСТВЕ РЕГЕНЕРАТИВНОГО АГЕНТА ПРИ ПОВРЕЖДЕНИЯХ КОЖИ

FGF-18 В ПРОЦЕДУРАХ ПЕРЕСАДКИ ТРАНСПЛАНТАТА И ТКАНЕВОЙ ИНЖЕНЕРИИ

ПЛАСТЫРЬ, СОДЕРЖАЩИЙ ЭКСТРАКТ ЛУКА

КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВ СВЯЗАННЫХ С КИШЕЧНОЙ ПРОНИЦАЕМОСТЬЮ

НОВОЕ ЛЕЧЕНИЕ ХРОНИЧЕСКИХ ЯЗВ

НОВЫЕ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ

... 1. Композиция для стимулирования роста волос у млекопитающих, содержащая:a) модифицированный полипептид остеопонтина, в котором RGD домен инактивирован, иb) фармацевтически приемлемый и/или косметически приемлемый наполнитель, носитель или растворитель.2. Композиция по п. 1, в которой полипептид обладает свойством стимулировать рост волос человека.3. Композиция по п. 1, в которой полипептид обладает свойством стимулировать рост волос in vivo.4. Композиция по п. 1, в которой полипептид обладает свойством стимулировать имеющиеся волосяные фолликулы.5. Композиция по п. 1, в которой полипептид обладает способностью индуцировать образование новых волосяных фолликулов или стволовых клеток, образующих такие фолликулы.6. Композиция по п. 1, в которой длина полипептида соответствует менее чем 500 аминокислотным остаткам, например, менее чем 400, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250, 200, 150, 100, 50, 40, 30, 20, 15, 10 или менее аминокислотным остаткам.7. Композиция по пункту 6 ...

КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ РАН И ОЖОГОВ

... 1. Применение жидкой композиции для получения лекарственного средства для лечения открытых ран и ожогов, где указанная композиция включает компонент (а), выбранный из солей, содержащих катионы Аn+ и анионы, образованные оксидами галогенов согласно общей формуле [ОmХ]-, где А представляет собой металл, выбранный из группы 1 или 2 Периодической системы элементов, Х представляет собой атом галогена, m=1-4, n=1 или 2, компонент (b), выбранный из группы доноров кислорода, и компонент (d), выбранный из группы жидких связующих. 2. Применение жидкой композиции для получения лекарственного средства для лечения открытых ран и ожогов, где указанная композиция получена объединением, по меньшей мере, компонента (а), выбранного из солей, содержащих катионы Аn+ и анионы, образованные оксидами галогенов согласно общей формуле [ОmХ]-, где А представляет собой металл, выбранный из группы 1 или 2 Периодической системы элементов, Х представляет собой атом галогена, m=1-4, n=1 или 2, компонента (b), выбранного ...

ПОВЯЗКА С ПРОЛОНГИРОВАННЫМ ВЫДЕЛЕНИЕМ АКТИВНЫХ ВЕЩЕСТВ

... 1. Повязка, содержащая по меньшей мере одну микроадгезивную граничную поверхность, причем указанная микроадгезивная граничная поверхность содержит по меньшей мере одно соединение, выбранное из полисульфатированных олигосахаридов, содержащих 1-4 моносахаридных звена, их солей и их комплексов, причем указанная повязка была обработана этиленоксидом.2. Повязка по п. 1, причем полисульфатированное олигосахаридное соединение выбрано из- калиевой соли октасульфата сахарозы,- соли серебра и октасульфата сахарозы,- комплекса гидроксиалюминия и октасульфата сахарозы.3. Повязка по п. 1 или 2, которая содержит от 0,5 до 2 мг/см, предпочтительно от 0,7 до 1,9 мг/см, благоприятно от 0,9 до 1,7 мг/смсоединения, выбранного из полисульфатированных олигосахаридов с 1-4 моносахаридными звеньями, их солей и их комплексов.4. Повязка по п. 1, в которой микроадгезивная граничная структура является эластомерной адгезивной композицией.5. Повязка по п. 1, причем микроадгезивная граничная поверхность содержит:- от ...

Verfahren zur Herstellung von Haut- oder Wundauflagen mit verkapselten, wundheilungsfördernden und/oder hautpflegenden Substanzen

PHARMAZEUTISCHE TOPISCHE ZUBEREITUNGEN ZUR FOERDERUNG DER WUNDGRANULATION UND EPITHELISATION

Fixation devices for tissue repair

THERAPEUTIC DRESSING

An oxygen generating and carbon dioxide absorbing wound dressing

Free radical scavenging wound powder

Uric acid as monovalent urate is a potent endogenous antioxidant protecting against free radical damage in man and other animals. The free radical peroxynitrite is implicated in non-healing chronic wounds. Urate is a most efficient scavenger of peroxynitrite forming a reduced radical capable of regeneration back into urate in the presence of ascorbate or thiols. Uricase a ubiquitous enzyme, although absent in human tissues, converts urate to allantoin the latter having potent angiogenic wound healing properties. Persistent bacteria, common in chronic non-healing wounds, would generate allantoin from topically applied urate. Synthetic urate spheres formed in a cation rich aqueous solution at ambient temperature, are extracted in ethanol and air-dried to the wound powder. These spheres show stability in various physiological media and added to the low solubility of urate, ensures prolonged local tissue activity; also precluding the risk of systemic absorption causing gout, although excessive ...

Wound dressings for the controlled release of therapeutic agents

Element for implantation in body tissue, particularly bone tissue

In an element for implantation in body tissue, particularly bone tissue, consisting of a biologically flawless material with a micro-pitted surface, the pores in the surface have a diameter many times smaller than has been previously known in order to permit the occurrence of such a tight and extensive boundary zone around the implanted element that this achieves reinforced and inextricable anchoring in the tissue. The pore diameter may be as little as about 10 nm and as large as a few multiples of the normal diameter of the cells in the tissue, preferably no larger than the cell diameter, i.e. about 1000 nm. Optimal results are obtained with pore diameters equal to or smaller than about 300 nm and a finely pored rutile layer has been found to give a particularly strong and durable joint with the growing tissue. Preferably at least one deposit of an agent facilitating and/or accelerating the growing-together process is arranged on or in the element. The element may be shaped with grooves ...

Use of perfluorocarbon as burn treatment

The novel treatment of a burn victim involves contacting a burn with a substantially fluorinated carbon material or a mono- or a di-brominated derivative thereof having an oxygen transport ability, an emulsion containing the material or a combination thereof.

DRUG DELIVERY COLLAGEN-IMPREGNATED SYNTHETIC VASCULAR GRAFT

Implantable materials and methods for inhibiting tissue adhesion formation

Device

Treatment of wounds

COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS

COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS

COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS

INTERLACED BIOACTIVE HYDRAULIC GEL STENCILS

USE OF A HEMOGLOBIN FOR THE PRODUCTION OF FEDERATIONS AND FROM THIS RESULTING FEDERATIONS

USE OF POLYSACCHARIDEN IN PREPARATIONS TO WUNDBEHANDLUNG.

USE OF PROTEASE NEXIN-I TO THE CICATRISATION

INPLANTAT WAITER SURFACES MODIFICATION WITH BIOACTIVE KONJUGATEN FOR IMPROVED INTEGRATION

PROMOTION OF THE CICATRISATION THROUGH CHEMICALLY MODIFIED TETRACYCLINE

SILVER-CONTAINING BIO GLASS COMPOSITIONS, THE OF SOL-GEL CONDITIONS DERIVED

MEDICAL DEVICE WITH NUCLEUS-ACID SYNTHETIC SURFACE TO IN-VIVO INDUCTION OF ITS ENDOTHELIALISIERUNG

MACROSCOPICALLY ORIENTATION CELL ADHESION PROTEIN TO WUNDBEHANDLUNG

USE OF A POLYSACCHARIDS FROM THE BACTERIUM VIBRIO DIABOLICUS TO THE CICATRISATION WITH THE BONE

DIAPHRAGM WITH CURVED SURFACE FOR THE GUIDANCE OF THE FABRIC

COMPOSITION CONTAINING EUGENOL AND POLYPHENOLE, USE OF SUCH A COMPOSITION TO THE CICATRISATION

ARTICLE WITH STICK-ABLE SURFACE

STRUCTURED OKKLUSIVER FEDERATION

COMPOSITIONS AND PROCEDURES FOR THE IMPROVEMENT OF THE INTEGRITY OF ATTACKED BODY PASSAGE WAYS AND CAVES

Dosing regimens for treating hypoxia-associated tissue damage

Described herein are methods for the treatment of hypoxia-associated tissue damage in subjects. More particularly, the methods relate to treating hypoxia-associated tissue damage in a subject during a surgical procedure according to particular dosing regimens. Specifically, the methods concern a dosing scheme comprising dosing a subject during a surgical procedure wherein the first dose is administered to the subject within about 120 minutes following an initial surgical incision made during the surgical procedure.

Osteoinductive calcium phosphates

The invention relates to a porous osteoinductive calcium phosphate material having an average grain size in a range of 0.1-1.50 m, having a porosity consisting essentially only of micropores in a size range of 0.1-1.50 m, and having a surface area percentage of micropores in a range of 10-40%..

Scaffolds for cell transplantation

A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.

Composite bone repair material

The present invention relates to a sliceable composite bone repair material comprising a porous block-shaped ceramic scaffold and a stabilizing polymer disposed therein. Said ceramic scaffold is a synthetic ceramic material or a naturally-derived material. Additionally said scaffold comprises interconnected macropores.

Activated leukocyte conditioned supernatant and uses for wound healing

Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds.

Scaffolds for cell transplantation

Coating method and coating device

Abstract Coating Method and Coating Device s The invention relates to a method for coating, at least regions of, a medical implant, prefera bly of an artificial joint or a fixation for a joint, whereby a medical implant having a surface to be coated is provided and the medical implant surface to be coated is contacted with a powder that comprises at least one pharmaceutically active substance and/or one bone growth-promoting sub stance, whereby powder is transferred to the surface of the implant through the contacting, and at 1o least part of the powder adheres to the surface to be coated after the contacting. The invention also relates to a device for coating, at least regions of, a medical implant using said method, whereby the device contains a powder, whereby the powder comprises at least one pharmaceutically active substance and/or one bone growth-promoting substance such that the powder can be transferred to the medical implant when a medical implant is contacted.

Gradient coating for biomedical applications

H:\tb\Intrwovn\NRPortbl\DCC\TXB09264 L.docx-8/10/2015 The present invention provides a coating comprising a bioactive material and an antimicrobial agent, wherein the concentration of said antimicrobial agent varies throughout the thickness of the coating.

Polymeric biomaterials derived from phenolic monomers and their medical uses

The present invention provides new classes of phenol compounds, including those derived 5 from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processability are useful in a variety of medical applications, such as in medical devices 10 and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.

Compositions and methods for treating and preventing tissue injury and disease

The present invention provides novel compositions comprising multipotent ceils or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated virases, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.

Medical devices containing shape memory polymer compositions

The present invention relates at least in part to surgical devices which comprise a shape 5 memory polymer material composition. Particularly, although not exclusively, the present invention relates to a fixation device e.g. an anchor device e.g. a suture anchor which comprises a shape memory material. Included in the present invention are anchor devices e.g. suture anchors which are formed entirely of a shape memory polymer material. Embodiments of the present invention comprise hybrid suture anchors, particularly suture .0 anchors which are formed from a shape memory polymer material and a non-shape memory material. Methods of securing an anchor in a bone or tissue are also included in the present invention.

Sustained-release drug carrier composition

The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.

Scaffold system for tissue repair

A device for treating a damaged tissue includes an expandable scaffold positionable in a portion of a luminal tissue structure of a mammal; and maintained via stent technology, wherein the scaffold is comprised of electrospun fibers composed of a biodegradable compound. The scaffold serves as a temporary template that allows the tissue to be rebuilt.

Muscle cell patches and uses therefor

Disclosed herein are contractile cell constructs comprising contractile cells, or progenitors thereof, adhered to a surface of a three dimensional fibroblast containing scaffold (3DFCS) and methods for using them to treat disease. In one aspect, the present invention provides methods for preparing a contractile construct, comprising (a) seeding immature contractile cells onto the surface of a three dimensional fibroblast containing scaffold (3DFCS) to produce a contractile construct; and (b) culturing the contractile construct under conditions to promote differentiation of the immature contractile cells into mature contractile cells, wherein the mature contractile cells form striations. In a further aspect, the invention provides methods for treating a disorder characterized by a lack of functioning contractile cells, comprising contacting a patient with a contractile cell-based disorder with an amount effective to treat the disorder with the construct of any embodiment or combination of ...

Fenestration kits for making fenestrated placental tissue allografts and methods of using the same

Described herein are fenestrated placental tissue allografts, methods for using the same for treating wounds that produce an exudate and to promote the healing process, and apparatus and kits for making the same that minimize or eliminate cross-contamination with placental tissue from other placental donors.

Polymeric biomaterials derived from monomers comprising hydroxyacids and phenol compounds and their medical uses

The present invention provides new classes of phenolic compounds derived from hydroxyacids and tyrosol or tyrosol analogues, useful as monomers for preparation of biocompatible polymers, and the biocompatible polymers prepared from these monomelic hydroxyarid-phenolic compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbability and processibility are useful in a variety of medical applications., such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric hydroxy acid-phenolic compounds and biocompatible polymers.

Multipotent and immunocompatible stem cell concentrate

The present invention generally relates to a stem cell concentrate isolated from a mammalian vascularized adipose tissue, biopharmaceuticals containing such concentrate and use thereof in therapies for treating diseases in mammals.

Modular device & interface design

Herein described is an osseointegrated interface device for engagement with an amputated limb including the skin comprising: a cap portion engageable with an osseointegrated device; wherein the cap portion comprises a surrounding flange; and wherein in use the surrounding flange receives the skin of the amputated limb at a distance spaced from the osseointegrated device.

Amniotic membrane powder and its use in wound healing and tissue engineering constructs

The present invention includes compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane powder. The compositions of the present invention comprise amniotic membrane powder and a scaffold. The methods of the present invention comprises applying a composition of the present invention to a subject to induce wound healing and tissue regeneration.

ORTHOPAEDIC IMPLANT HAVING A CRYSTALLINE CALCIUM PHOSPHATE COATING AND METHODS OF MAKING THE SAME

... -91 An orthopedic implant having a metal surface and a calcium phosphate layer disposed on at least part of the metal surface is described. The calcium phosphate layer has an average crystallite size of less than about 100 nm in at least one direction and dissolves for more than 2 hours in vitro. The calcium phosphate layer is substantially free of carbonate. The coating, which is formed on a sodium titanate surface, has increased shear strength and tensile strength. The coating is formed by a solution deposited hydroxyapatite process under inert conditions. The pH of the solution varies by less than 0.1 pH unit/hour during coating formation. 3566178vl ...

Structured occlusive dressings

Time release odor control composition and disposable absorbent article utilizingsame

Polyphosphate for use in promoting wound healing and scar abatement

DRUG DELIVERY COLLAGEN SYNTHETIC VASCULAR GRAFT

A collagen-impregnated vascular graft including drug materials complexed with the collagen to be released slowly from the graft following implant. The graft is a porous synthetic vascular graft substrate having collagen fixed to the graft substrate and cross-linked in situ to render the porous substrate blood-tight. The drug materials complexed with the collagen fibrils may include antithrombic agents, antibacterial, antimicrobial agents, antifungal agents and the like.

ADHESIVE BANDAGE

An adhesive bandage comprising a pad for absorbing a medicine which is separately stored from the pad by means of a medicine covering film interposed between the medicine and the adhesive tape or by means of a capsule enclosing the medicine in it until the bandage is applied to a local site of body such as wound, an adhesive tape carrying the pad thereon, a release sheet provided with a blister portion adapted to placing the medicine in it and attached to the adhesive tape in such a manner that the open side of the blister may face the adhesive tape.

BIODEGRADABLE POLYMERIC ENDOLUMINAL SEALING PROCESS, APPARATUS AND POLYMERIC PRODUCT FOR USE THEREIN

A novel process for paving or sealing the interior surface of a tissue lumen by entering the interior of the tissue lumen and applying a polymer to the interior surface of the tissue lumen. This is accomplished using a catheter which delivers the polymer to the tissue lumen and causes it to conform to the interior surface of lumen. The polymer can be delivered to the lumen as a monomer or prepolymer solution, or as an at least partially preformed layer on an expansile member.

BIODEGRADABLE POLYMERIC ENDOLUMINAL SEALING PROCESS, APPARATUS AND POLYMERIC PRODUCTS FOR USE THEREIN

A novel process for paving or sealing the interior surface of a tissue lumen by entering the interior of the tissue lumen and applying a polymer to the interior surface of the tissue lumen. This is accomplished using a catheter which delivers the polymer to the tissue lumen and causes it to conform to the interior surface of lumen. The polymer can be delivered to the lumen as a monomer or prepolymer solution, or as an at least partially preformed layer on an expansile member.

USE OF CREATINE COMPOUNDS FOR TREATMENT OF BONE OR CARTILAGE CELLS AND TISSUES

The method, composition and use of the composition for healing defects in bone or cartilage tissue in animals and humans caused by trauma or surgery is disclosed. The method comprises administration of creatine compounds including analogues or pharmaceutically acceptable salts thereof. Treatment in accordance with this method speeds-up time for and improves the process of healing of defects in bone or cartilage tissue in animals and humans caused by trauma or surgery including acceptance and bonding of artificial implants. The treatment with creatine compounds can be therapeutic for diseased patients, preventive for healthy people as well as geriatric for elderly people.

HYDROGEL-CONTAINING MEDICAL ARTICLES AND METHODS OF USING AND MAKING THE SAME

NANOFIBER-HYDROGEL COMPOSITES FOR CELL AND TISSUE DELIVERY

A soft tissue device can incorporate a composite material comprising a gel and at least one nanostructure disposed within the gel. A soft tissue device can further incorporate biologically active materials such as cells, tissues. A method for healing a soft tissue defect while promoting soft tissue regeneration can include applying a soft tissue device to a soft tissue defect, wherein the composite material includes a gel and a nanostructure disposed within the gel. A method for manufacturing a soft tissue device for use in healing soft tissue defects can include providing a gel, disposing nanofibers within the gel, and a biologically active material.

DOSING REGIMENS FOR TREATING HYPOXIA-ASSOCIATED TISSUE DAMAGE

Described herein are methods for the treatment of hypoxia-associated tissue damage in subjects. More particularly, the methods relate to treating hypoxia-associated tissue damage in a subject during a surgical procedure according to particular dosing regimens. Specifically, the methods concern a dosing scheme comprising dosing a subject during a surgical procedure wherein the first dose is administered to the subject within about 120 minutes following an initial surgical incision made during the surgical procedure.

METHODS AND COMPOSITIONS RELATED TO EXTRACELLULAR MATERIAL DERIVED FROM HYPERTONIC CELL SOLUTIONS

Disclosed herein are compositions, kits, and methods involving hypertonic solutions. Specifically, disclosed herein are methods and compositions used for increasing the yield of extracellular material from cells. This occurs when said cells are exposed to hypertonic solutions.

DRUG-DELIVERING NERVE WRAP

Described herein are medical film materials that incorporate one or more neuro-regenerative drugs into a polymer film. The polymer film includes a copolymer of lactide and caprolactone. The neuro-regenerative drug includes the macrolactam immunosuppressant FK506. The film is configured such that when placed under physiological conditions, the neuro-regenerative drug is released in an extended, substantially linear fashion for a period of at least 30 days.

DERIVATION OF HUMAN SKIN ORGANOIDS FROM PLURIPOTENT STEM CELLS

Provided herein are methods for directing differentiation of human pluripotent stem cells into a three-dimensional multilayered skin composition comprising an epidermal layer, a dermal layer, and a plurality of cells capable of forming a functional hair follicle. Also provided herein are three-dimensional, multilayered engineered skin compositions and methods of using the same for drug screening, for screening compounds for effects on hair growth, and for other applications.

SYNTHETIC HYDROGEL CARRIERS FOR MUSCLE REPAIR

Disclosed herein are hydrogels that can be loaded with myogenic agents, for instance muscle stem cells (MuSCs)/satellite cells, pro-myogenic factors, and combinations thereof. The hydrogels can be contacted with damaged muscle tissue, thereby facilitating muscle growth and repair. Further provided are methods of repairing muscle tissue in a patient in need thereof, said methods comprising contacting the muscle tissue with a composition comprising the hydrogel. Also provided herein are kits comprising the hydrogel composition and a substrate comprising at least one microneedle.

COMPOSITIONS AND METHODS FOR IMPROVING CARDIAC FUNCTION

The present invention provides compositions and methods for improving cardiac function. Specifically, the present invention provides compositions and methods for treating a subject having a disorder or condition associated with aberrant cardiac tissue function, comprising contacting a patient having a disorder or condition associated with aberrant cardiac tissue function with a construct, or a construct associated with therapeutic cells, or a construct associated with fibroblast cells and therapeutic cells.

DRESSING AND A METHOD FOR THE MANUFACTURE THEREOF

ACELLULAR BIOABSORBABLE TISSUE REGENERATION MATRICES PRODUCED BY INCUBATING ACELLULAR BLOOD PRODUCTS

AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND METHODS OF USE

Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF-.beta.; signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.

COMPOSITIONS AND METHODS FOR REGENERATION OF HARD TISSUES

Bone graft compositions including bioactive glass scaffold and characterized in that the bioactive glass scaffold has a high compressive strength, is osteoconductive and osteostimulative and resorbs at a rate consistent with the formation of new bone are described. Also, methods of using the bone grafts for regeneration of hard tiss ues and, especially, for treating or correcting developmental dysplasia of the hip are provided.

COMPOSITIONS AND METHODS FOR IMPROVING SKIN QUALITY

Provided herein are methods for improving skin quality in a subject comprising administering to the skin a pharmaceutical composition comprising a polypeptide covalently bound to a hydrophilic polymer and/or a polysaccharide covalently bound to a hydrophilic polymer.

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TISSUE INJURY AND DISEASE

The present invention provides novel compositions comprising multipotent ceils or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated virases, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.

VACUUM EXPANDED DRY COMPOSITION AND SYRINGE FOR RETAINING SAME

The present disclosure relates to a method for vacuum expansion of a paste prior to freeze-drying said paste to achieve a dry paste composition which reconstitutes efficiently to form a flowable paste upon addition of an aqueous medium. The present disclosure further relates to a syringe for retaining a dry paste composition in a vacuum.

INJECTABLE IN SITU POLYMERIZABLE COLLAGEN COMPOSITION

The present invention is directed to injectable acid soluble collagen compositions comprising a neutralized solution of an acid soluble collagen, EDTA and preferably a polyol, wherein the composition is injectable at physiological pH and the acid soluble collagen polymerizes upon exposure to tissue. The invention is suitable for use in soft tissue augmentation, promoting soft tissue regeneration and coating medical implants and devices.

METHODS OF MANUFACTURING BIOACTIVE GELS FROM EXTRACELLULAR MATRIX MATERIAL

The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.

METHODS OF REMOVING ALPHA-GALACTOSE

Tissue products lacking a desired percentage of immunogenic epitopes, such as galactose alpha-1,3 galactose epitopes, are provided. Methods of making and using the tissue products are also provided.

PROCESSED BONE PARTICLE COMPOSITIONS AND RELATED METHODS

Bone particle compositions and kits are provided that include a biologically-resorbable cement and a plurality of processed bone particles. A first portion of the processed bone particles in the compositions have a shape configured to interconnect with one another, while a second portion of the processed bone particles having an irregular shape. Methods for treating a bone defect are also provided wherein an effective amount of the bone particle compositions are administered to a site of a bone defect in a subject.

PHARMACEUTICAL PREPARATION AND METHOD OF ITS PRODUCTION AND USE

Thus, the present invention provides a composition in powder form comprising highly dispersed silica particles, polymethylsiloxane particles, and a cationic surfactant, wherein at least 25 % by weight of the cationic surfactant is present in primary polymethylsiloxane particles carrying the cationic surfactant on their surface and/or in agglomerates of these primary particles.

CHEMICAL GRADIENTS

In one aspect, apparatuses for providing chemical gradients are described herein. In some embodiments, an apparatus described herein comprises a conduit having a first end and a second end, one or more microchannels disposed in the conduit and extending from the first end toward the second end, and a fiber coiled around the exterior of at least one microchannel, wherein the fiber comprises an active agent that is operable to diffuse into the interior of the microchannel.

INFUSION SET ADHESIVE SYSTEMS

Improvements in an adhesive patch for an infusion set include the addition of an antiperspirant, wound healing and/or antimicrobial agent to the adhesive surface, and the layering of different backing materials to improve performance characteristics of the patch. Patches may be offered as part of a product line, in which differently shaped patches are provided for attachment to different parts of the body, and different pressure sensitive adhesives provide different peel strength according to different use patterns of the end user.

PROCESS FOR MANUFACTURING A CAP OF A COVERING DEVICE FOR A BONE DEFECT SITE; DEVICE FOR COVERING AND/OR RECONSTRUCTING A BONE DEFECT SITE

A method for producing an attachment piece (4), which has at least one predetermined break point (16), a cover device for a bone defect site (2), and a device (1) for covering and/or reconstructing a bone defect site (2) are proposed, wherein by comparing a first data set, which represents the affected bone defect site (2) in the actual state, against a second data set, which represents the desired state of a bone regenerated at the bone defect site (2), wherein the second data set was calculated or was recorded at a time when the bone at the site now to be regenerated was still a healthy bone (18), it is possible that the regenerated bone, which arises through the regeneration of the bone defect site (2), has a form corresponding to the form that the bone at the site to be regenerated had when it was still healthy.

DRUG DELIVERY MATRICES TO ENHANCE WOUND HEALING

The invention provides a more efficient entrapment of bioactive molecules within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule is deglycosylated to reduce its effective solubility in the matrix to retain it more effectively within the matrix. Preferably the bioactive factors are deglycosylated members of the cystine knot growth factor superfamily, and particular within the TGF.beta. superfamily.

Activated leukocyte composition and uses for wound healing

Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds.

Wound healing device

A plasma coating device for treating a wound comprises a plasma chamber having: one or more electrodes, a gas supply inlet, a plasma outlet exposed to ambient pressure, and an ignition system operatively connected to the electrodes for providing a non-thermal equilibrium plasma within the plasma chamber. An aerosol delivery system is operable to introduce a bioresorbable material as an aerosol into the plasma, to produce a coating on the wound surface.

Osteoconductive matrices comprising statins and methods of using the same

Osteoconductive matrices and methods are provided that have one or more statins disposed therein. The matrices may be injected into a fracture site. The osteoconductive matrices provided allow for sustain release of the statin and facilitate bone formation and repair of the fracture site.

Umbilical cord amniotic membrane products

Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM.

Biomolecular coating for implants

Methods and compositions are provided for improving tissue growth and device integration in vivo. Substrates and devices coated with an α 2 β 1 or α 5 β 1 integrin-specific ligand are provided. The substrates and devices coated with an α 2 β 1 or α 5 β 1 integrin-specific ligand are shown to have greater tissue formation on the surface relative to controls, in particular greater bone formation.

Compositions and improved soft tissue replacement methods

The specification discloses compositions and methods for treating a soft tissue defect of an individual.

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

Synthetic scaffolds and organ and tissue transplantation

Articles, compositions, and methods for growing tissues and organs using bioreactors, including rotating bioreactors, are provided. Synthetic scaffolds for growing artificial tissue and organ transplants are also provided.

Bioactive Substance in a Barbed Suture

Barbed surgical sutures are provided which include an elongated body and a plurality of barbs extending therefrom. A bioactive agent is disposed within barb angles formed between the barbs and the elongated body. The barbs may be made from a shape memory polymer having a permanent shape which may be deformed to a temporary shape, such that barbs of the suture extend at different barb angles in the different shape configurations. The barb angles of the permanent shape may be greater than the barb angles of the temporary shape, thereby exposing and/or releasing a bioactive agent after placement in tissue.

Compositions for Regenerating Defective or Absent Myocardium

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

Polymeric biomaterials derived from phenolic monomers and their medical uses

The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.

Injectable chitosan mixtures forming hydrogels

A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., that includes at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions.

Activated Leukocyte Composition and Uses For Wound Healing

Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds.

Synthetic scaffolds and organ and tissue transplantation

Articles, compositions, and methods for growing tissues and organs using bioreactors, including rotating bioreactors, are provided. Synthetic scaffolds for growing artificial tissue and organ transplants are also provided.

COMPOSITION FOR THE TREATMENT OF A BONE FRACTURE

There is disclosed a composition formed by a reaction of at least one component A and at least one component B, wherein component A is selected from among a compound comprising having at least two thiol-groups and a disulfide derivative of a compound having at least two thiol groups, and wherein component B is a compound having at least two vinyl reactive groups, for the manufacture of an implant for the treatment of a bone fracture. Advantages include that the adhesive patch formed by the composition will be solid in body fluid upon curing and will exhibit excellent mechanical strength. Advantages include that the composition is biocompatible, the material can be applied in small and inaccessible areas, the process requires less surgeon training, it solves drawback with open surgery, and it is possible to use cost effective materials and methods in the process. 1. A patch for treating a bone defect , comprising:a layer comprising a primer; anda composition provided on said layer, wherein the composition comprises a reaction product of a component A and a component B, whereincomponent A comprises at least one compound comprising at least two thiol groups or at least one disulfide derivative of a compound comprising at least two thiol-groups,component B comprises at least two vinyl reactive groups chosen from vinyl, acrylates, methacrylates, allyl and unsaturated cyclic vinyls, andat least one compound of component A or of component B comprises at least one group selected from a hydroxyl group, a carboxyl group, a dopamine group and a phenol group; andthe primer is a compound comprising a phenol group and one group selected from acrylate, methacrylate, an allyl, a vinyl and an unsaturated ring and wherein the phenol group is selected from p-hydroxyl phenyl, 3,5-dihydroxyphenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2,4-dihydroxyphenyl, 2,5-dihydroxyphenyl, 3,4-dihydroxyphenyl, 3,5-dihydroxyphenyl and 3,4,5-trihydroxyphenyl.2. The patch according to claim ...

Liquid Crystalline Collagen Materials and Use in Connective Tissue Repair

Compositions and methods are provided to accelerate and improve wound repair and reconstruction of connective tissue structures, including tendons, by assembly of collagen using liquid crystalline collagen. The compositions and methods can be used to treat various forms of connective tissue injury or to prevent or slow degeneration to vulnerable tendons that are generally refractory to repair. 1. A non-naturally occurring , stable , liquid crystal collagen composition , wherein the composition comprises type I , II , III , V , and/or XI collagen organized into fibril-like structures 50-200 nm in diameter , wherein the fibril-like structures are locally aligned along their longitudinal axis and have D-periodic banding structure larger than about 67 nm , and wherein the composition has a density of at least about 500 mg/mL.2. The collagen composition of claim 1 , wherein the fibril-like structures shed monomeric collagen at a rate less than 1% per day at 37° C.3. The collagen composition of claim 1 , wherein the composition has a density of about 800 mg/mL.4. A non-naturally occurring claim 1 , metastable claim 1 , liquid crystal collagen composition claim 1 , wherein the composition comprises type I claim 1 , II claim 1 , III claim 1 , V claim 1 , and/or XI collagen organized into fibril-like structures 50-100 nm in diameter claim 1 , wherein the fibrils are locally aligned along their longitudinal axis and substantially lack native D-periodic banding structure claim 1 , and wherein the composition has a density in the range from about 100 to about 500 mg/mL.5. A bi-stable liquid crystal collagen composition comprising the composition of and the composition of .6. The bi-stable liquid crystal collagen composition of claim 1 , wherein the relative amounts of the composition of and the composition of are selected to provide a desired collagen delivery rate in a collagen assembly process.7. The composition of any one of - configured as a plurality of particles claim 1 , ...

SKIN PROTECTANT FILM INCLUDING SKIN HEALTH INGREDIENTS

A no-sting skin protectant film forming composition is formulated with a film forming polymer having both polar and nonpolar characteristics, a no-sting nonpolar solvent system, and at least one skin health ingredient. The no-sting skin protectant film forming composition is configured to form a protective film on a skin surface after the solvent system evaporates. 1. A no-sting skin protectant film forming composition , comprising:at least one film forming polymer having both polar and nonpolar characteristics;a solvent system, the solvent system being a no-sting and nonpolar solvent system; andat least one skin health ingredient;wherein the no-sting skin protectant film forming composition is configured to form a protective film on a skin surface after the solvent system evaporates.2. The no-sting skin protectant film forming composition of claim 1 , wherein the at least one film forming polymer comprises a vinylpyrrolidone-eicosene copolymer.3. The no-sting skin protectant film forming composition of claim 1 , wherein the solvent system comprises C7-C8 isoparaffin.4. The no-sting skin protectant film forming composition of claim 1 , wherein the at least one skin health ingredient comprises ceramide.5. The no-sting skin protectant film forming composition of claim 1 , wherein the at least one skin health ingredient comprises a blend of ceramide claim 1 , cholesterol claim 1 , and stearic acid.6. The no-sting skin protectant film forming composition of claim 1 , further comprising alpha-Tocopherol.7. The no-sting skin protectant film forming composition of comprising about 90 weight/weight percent (w/w %) to about 97 w/w % of the solvent system claim 1 , about 3 w/w % to about 10 w/w % of the at least one film forming polymer claim 1 , and about 0.01 w/w % to about 0.05 w/w % of the at least one skin health ingredient.8222. The no-sting skin protectant film forming composition of comprising about 90 w/w % to about 97 w/w % of C7-C8 isoparaffin claim 1 , about 3 w/w ...

HOMEOPATHIC THERAPEUTIC METHOD AND COMPOSITIONS

Methods of producing a Hydrophilic Homeopathic Aqueous Substance Active (HASA)-gel matrix, include the steps of: (a) combining a homeopathic compound and an uninhibited aqueous composition to produce a HASA; (b) combining the HASA with at least one hydrophilic gelling agent; and (c) thereafter, forming the hydrophilic HASA-gel matrix by use of at least one of a thickening agent, a crosslinking agent, or a polymerization agent. 130-. (canceled)31. A method of producing a hydrophilic homeopathic gel matrix , the method comprising the steps of: (a) combining diluted aqueous homeopathic composition comprising a homeopathic compound and uninhibited water at a homeopathic compound-to-water ratio of no more than 0.000001 with at least one hydrophilic gelling agent to produce a solution comprising the hydrophilic gelling agent and the diluted aqueous homeopathic composition; and (b) forming the hydrophilic homeopathic gel matrix by crosslinking or polymerizing the solution comprising the hydrophilic gelling agent with the diluted aqueous homeopathic composition.32. The method of claim 31 , wherein the diluted aqueous homeopathic composition comprises the homeopathic compound and uninhibited water at a ratio of no more than 0.00000001.33. The method of claim 31 , wherein the diluted aqueous homeopathic composition comprises the homeopathic compound and uninhibited water at a ratio of no more than 0.00000000001.34. The method of claim 31 , wherein the hydrophilic homeopathic gel matrix comprises at least about 50% by weight of the diluted aqueous homeopathic composition.35. The method of claim 31 , wherein the hydrophilic homeopathic gel matrix comprises at least about 60% by weight of the diluted aqueous homeopathic composition.36. The method of claim 31 , wherein the hydrophilic homeopathic gel matrix comprises at least about 80% by weight of the diluted aqueous homeopathic composition.37. The method of claim 31 , wherein the hydrophilic homeopathic gel matrix comprises ...

Compositions and Methods for Wound Treatment

Methods of treating a wound of a subject using a composition which includes graphene oxide (GO) and hyaluronic acid (HA) that are covalently linked, XAV939, and water. The composition can also include a surfactant, such as PEG. The composition can be topically administered to a subject to treat a wound of the subject. 1. A method of treating a cutaneous wound in a subject , comprising contacting the wound with an effective amount of a composition , the composition comprising:a matrix component comprising a graphene oxide (GO) and hyaluronic acid (HA) conjugate (GO-HA), wherein the GO and HA are covalently linked via a linker;XAV939; andwater, wherein XAV939 constitutes from about 0.001 wt % to about 5 wt % of the total composition.2. The method of claim 1 , wherein the composition further comprises polyethylene glycol (PEG).3. The method of claim 2 , wherein the PEG has a molecular weight of from about 200 to about 400 Daltons.4. The method of claim 2 , wherein the PEG is in an amount of from about 0.1 wt % to about 20 wt % of the total composition.5. The method of claim 1 , wherein the composition further comprises a thickener.6. The method of claim 5 , where the thickener comprises hydroxypropyl cellulose (HPC).7. The method of claim 1 , wherein the linker comprises 2-25 carbons.8. The method of claim 1 , wherein the linker is straight-chained or branch-chained.9. The method of claim 1 , wherein the linker comprises one or more —CHCHO— units.10. The method of claim 1 , wherein the linker comprises —R—R—R— claim 1 , wherein Rand Rare each independently selected from the group consisting of —CO— claim 1 , —COO— claim 1 , —NH— claim 1 , —NH—NH— claim 1 , —NH—NH—CO— claim 1 , —CS— claim 1 , —S— claim 1 , and —O— claim 1 , and wherein Ris an unsubstituted or substituted linear alkylene group having 2-20 backbone carbons.11. The method of claim 10 , wherein Rand Rare each —NH—NH—CO—.12. The method of claim 1 , wherein the weight ratio of XAV939 to GO-HA in the ...

METHODS OF TREATING TISSUE VOIDS FOLLOWING REMOVAL OF IMPLANTABLE INFUSION PORTS USING ADIPOSE TISSUE PRODUCTS

Compositions and methods for treating tissue are provided. The compositions may include tissue matrix derived from adipose tissue suitable for injection, small-volume implantation, or use as a soft-tissue regenerative material. Also provided are methods for producing such compositions. 1. A method for treating a void in soft tissue comprising:removing an implanted infusion port from an anatomic location of a subject to create a void through a skin incision;delivering a flowable composition comprising an adipose-based tissue matrix into the void at a time proximate to the removing step; andclosing the skin incision.2. The method of claim 1 , wherein the composition is delivered before closing the incision.3. The method of claim 1 , wherein the composition is delivered after closing the incision.4. The method of claim 1 , wherein the anatomic location is an anterior chest wall.5. The method of claim 1 , wherein the delivering step comprises injecting the flowable composition through a needle inserted percutaneously.6. The method of claim 1 , wherein the delivering step comprises placement of the composition into the soft tissue dead space through an open surgical incision.7. The method of claim 1 , wherein the composition comprises a carrier that prevents dissipation of the adipose-based tissue matrix away from the void.8. The method of claim 1 , wherein the composition further comprises a glycosaminoglycan.9. The method of claim 8 , wherein the glycosaminoglycan is hyaluronic acid.10. The method of claim 9 , wherein the hyaluronic acid is a non-crosslinked hyaluronic acid.11. The method of claim 9 , wherein the hyaluronic acid is a crosslinked hyaluronic acid.12. The method of claim 9 , wherein the hyaluronic acid is present in the composition at a concentration by weight of about 2.5%.13. The method of claim 1 , wherein the composition comprises a local anesthetic.14. The method of claim 1 , wherein the adipose-based tissue matrix is in the form of a suspension of ...

FORMATION OF SEMI-PERMEABLE POROUS ARTIFICAL SCAB

Pourous semi-ermeable artificial self-attaching scab designed to protect the eroded or injured surfaces. 1. (canceled)2. An aqueous thixotropic fluid , comprising:1-5 weight % of azosulfamide, 0.004-0.007 weight % of gentian violet, 0.001-0.003 weight % of dexamethasone, 0.5-2 weight % of panthenol, and 0.03-0.06 weight % of gentamycin.3. The fluid according to claim 2 , wherein it is used topically as cicatrizing agent.4. The fluid according to claim 2 , wherein it is used for treating at least one of lesions claim 2 , wounds or burns. The present invention relates to artificial cicatrization means by means of which a substance is applied to the damaged surfaces, wounds, burns A-AB, after removing the necrotic tissue and disinfecting the damaged or burnt zone.The technique consists of the removal of the necrotic tissue from the injured zone and subsequent application of the artificial covering mentioned in the title. The preparation causes the formation of an artificial scab on the injured surface.The problems to be solved are:1. To replace the use of gauzes since they adhere to the damaged zone and cause lesions in the granulation zone when an attempt is made to remove them, thus causing defective cicatrizations.2. To avoid potential infections given that protection against external biological agents is provided.3. To avoid the loss of body fluids and heat, resulting from the loss of the integrity of the mechanical barrier.The porous artificial scab allows the formation of new tissue, allowing its natural respiration: during its regeneration and bringing about a faster development of cicatrization by avoiding disrupted processes such as the necrosis or the development of anaerobes, without the need to cover and without performing further treatments until the natural detachment of the “Scab.”*To protect the lesion against infections and losses of fluids with an artificial scab, and thus the cicatrization is much more rapid and the new tissue is not defective.*The ...

MICROPATTERNED SILICONE OXYGENATING DRESSING FOR CHRONIC WOUNDS

A wound dressing system having an oxygen-permeable membrane having a first surface and a second surface with oxygen-permeable pillars extending from the second surface is described. 1. A wound dressing system , comprising:a membrane comprised of an oxygen-permeable material, the membrane having a first surface and a second surface with oxygen-permeable pillars extending from the second surface; and interstitial spaces defined between the pillars;the pillars have sidewalls and end surfaces that are oxygen permeable and through which oxygen can diffuse three-dimensionally between and around the pillars;wherein the membrane is configured to be exposed to oxygen such that oxygen can diffuse from the first surface through the oxygen-permeable material toward and through the pillars; and,wherein, in use, the pillars are placed adjacent to the wound and are configured to allow direct delivery of the oxygen into cells of the wound.2. The wound dressing system of claim 1 , further including an oxygen delivery conduit within the membrane that allows oxygen to diffuse through the membrane and the pillars.3. The wound dressing system of claim 2 , wherein the oxygen delivery conduit comprises a porous conduit that extends through the membrane.4. The wound dressing system of claim 1 , further including an oxygen delivery system operatively connected to the membrane.5. The wound dressing system of claim 4 , wherein the oxygen delivery system comprises a supply of an oxygen-containing gas.6. The wound dressing system of claim 5 , wherein the supply of oxygen-containing gas comprises a portable canister.7. The wound dressing system of claim 4 , further includes a tubing that operatively connect the oxygen delivery system to the membrane.8. The wound dressing system of claim 1 , further including a covering on the first side of the membrane.9. The wound dressing system of claim 1 , wherein the oxygen-permeable material comprises an organosilicon polymer.10. The wound dressing system ...

Composite Matrix for Bone Repair Applications

Composite fibrous and non-fibrous matrices of biocompatible, bioactive synthetic polymers and ceramics are described. The composite matrices support bone cell differentiation and may be used alone or with whole bone marrow, isolated mesenchymal stem cells and/or bone grafts for bone repair and bone regeneration.

CROSSLINKED HYALURONIC ACID-COLLAGEN GELS FOR IMPROVING TISSUE GRAFT VIABILITY AND SOFT TISSUE AUGMENTATION

Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component. 1. A method of improving fat graft volume retention , the method comprising: water;', 'a crosslinked macromolecular matrix comprising hyaluronic acid crosslinked to collagen via a plurality of crosslink units, wherein at least a portion of the crosslink units comprise an amide bond, an ester bond or both; and the crosslinked macromolecular matrix has a weight ratio of the hyaluronic acid to the collagen of 1:1 to 7:1;', 'wherein said hydrogel component has a hyaluronic acid concentration of 6 mg/mL to 21 mg/mL and a collagen concentration of 3 mg/mL to 12 mg/mL; and, 'providing a hydrogel component, the hydrogel component comprisingblending the hydrogel component with a lipoaspirate to form a lipoaspirate/hydrogel graft, wherein the lipoaspirate/hydrogel graft has a lipoaspirate:hydrogel component volume ratio of 1:1 to 5:1; andadministering the lipoaspirate/hydrogel graft into a soft tissue in an area on a body of an individual, wherein the lipoaspirate/hydrogel graft promotes fat graft survival in the soft tissue area on the body.2. The method of claim 1 , wherein the soft tissue comprises a volume claim 1 , and the administering of the lipoaspirate/hydrogel graft increases the soft tissue volume of the area on the body.3. The method of claim 2 , wherein the administering of the lipoaspirate/hydrogel graft increases fat volume in the area on the body.4. The method of claim 3 , wherein retention of the fat volume is increased as compared to administering the lipoaspirate alone.5. The method of claim 1 , wherein the method reduces variability in retained fat graft volume retention obtained from the administered lipoaspirate/hydrogel graft in the ...

BIOABSORBABLE POLYMERIC COMPOSITION FOR A MEDICAL DEVICE

A crystallized bioabsorbable polymer scaffold comprises a polymer composition of poly (L-lactide-co-tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-ε-caprolactone) or poly (D-lactide-co-ε-caprolactone) in the form of block copolymers of blocky copolymers, wherein the scaffold is cold-bendable. 1. A crystallized bioabsorbable polymer scaffold comprising a polymer composition of poly (L-lactide-co-tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-ε-caprolactone) or poly (D-lactide-co-ε-caprolactone) in the form of block copolymers of blocky copolymers , wherein the scaffold is cold-bendable.2. The bioabsorbable polymer scaffold of claim 1 , wherein the scaffold is cold bendable at temperatures in a range of about 10° C. to about 30° C.3. The bioabsorbable polymer scaffold of claim 1 , wherein the polymer composition comprises poly (L-lactide-co-ε-caprolactone) or poly (D-lactide-co-ε-caprolactone).4. The bioabsorbable polymer scaffold of claim 1 , wherein the polymer composition comprises poly (L-lactide-co-ε-caprolactone).5. The bioabsorbable polymer scaffold of claim 1 , further comprising a poly (L-lactide) moiety or a poly (D-lactide) moiety or a poly L-lactide-co-PEG moiety or a poly D-lactide-co-PEG moiety.6. The bioabsorbable polymer scaffold of claim 1 , wherein the composition includes increased hydrophilicity and free molecular volume allowing for uptake of water.7. The bioabsorbable polymer scaffold of claim 1 , wherein the composition includes amorphous and semicrystalline polymer portions.8. The bioabsorbable polymer scaffold of claim 7 , wherein a crystallinity and tensile strength of the composition is adjustable by elongation of the semicrystalline portion.9. The bioabsorbable polymer scaffold of claim 1 , further comprising at least one radiopaque marker.10. A crystallized bioabsorbable polymer scaffold comprising a polymer composition of poly (L-lactide-co-tri- ...

Self-Assembling Biomimetic Hydrogels Having Bioadhesive Properties

The disclosure relates to a composition that is liquid at a temperature below the body temperature of a mammal and that solidifies at or above the body temperature of the mammal. The composition includes a thermally-desolubilizable polymer interspersed with a polymeric component of extracellular matrix and an encapsulated form of an amine compound (preferably an aminated component of extracellular matrix) that is de-encapsulated in the body of the mammal. The polymeric component is able to form covalent bonds with amine moieties in the aminated component, in one or more tissues in the body of the mammal, or both. Upon injection off liquid suspension of these components into the body of the mammal, the thermally-desolubilizable polymer condenses, entrapping the polymeric component. The polymeric component binds covalently with a tissue in the body, and the aminated component end-caps the remaining reactive moieties of the polymeric component, forming a matrix at the site of injection. The disclosure also relates to uses of such compositions for forming a matrix on or within the body of a mammal. The compositions have a variety of uses, such as bioadhesives, as sealants for ruptured tissues, as drug or imaging agent depots, or as mechanical cushions. 1101-. (canceled)102. A method of forming a solidified matrix fixed within the body of a mammal , the method comprising: a) a biocompatible thermally-desolubilizable (TD) polymer selected from the group consisting of poly(ethylene oxides) (PEOs), poly(propylene oxides) (PPOs), copolymers of PEO and poly(lactide acid) (PLA), poly (n-isopropyl acrylamides) (PNIPPAms), mixtures and copolymers thereof, wherein the polymer exists in an extended form below a critical solution temperature (CST) that is lower than the normal body temperature of the mammal and in a condensed form at or above the CST;', 'b) an aminated component of a mammalian extracellular matrix, in a releasable encapsulated form, wherein the aminated component ...

NEUROGENIC REGULATION OF BONE GROWTH AND BONE DEGRADATION

This disclosure relates to methods for promoting bone formation or reducing bone destruction. This disclosure also relates to methods for promoting the recruitment of mesenchymal stem cells (MSCs) to a local site of injury or surgical intervention in bone to promote healing. In addition, this disclosure relates to methods for reducing or preventing mineral formation or bone growth, or reducing bone mass. The methods disclosed herein are useful for treating conditions such as osteopetrosis or osteoradionecrosis. 110.-. (canceled)11. A method of treatment of orthopedic injuries or surgical interventions , comprising administering at least one polypeptide selected from the group consisting of netrin-1 , netrin-4 , slit1 , slit2 , slit3 , RGMa , and RGMb.12. The method of claim 11 , wherein said at least one polypeptide is selected from the group consisting of netrin-1 claim 11 , netrin-4 claim 11 , slit1 claim 11 , and slit2 claim 11 , and the administration promotes bone formation and/or reduces bone degradation.13. The method of claim 11 , wherein said at least one polypeptide is selected from the group consisting of slit3 claim 11 , RGMa claim 11 , and RGMb claim 11 , and the administration inhibits bone formation and/or promotes bone re-absorption.14. The method of claim 11 , wherein said at least one polypeptide is administered with a collagen based implant claim 11 , either in the form of a collagen sponge claim 11 , a powdered collagen claim 11 , or a collagen based gelatin hydrogel.15. The method of claim 14 , wherein the collagen based implant has alternating layers of polypeptides.16. The method of claim 15 , wherein the alternating layers of polypeptides are released over a period of time.17. The method of claim 15 , wherein the alternating layers of polypeptides include a layer of polypeptides that promote bone formation and/or reduce bone destruction claim 15 , and a layer of polypeptides that inhibit bone formation claim 15 , promote bone re-absorption ...

TECHNIQUES FOR TREATMENT OF ABSCESSES

This document provides devices, system, and methods for treating an abscess cavity. For example, procedures that involve supplementing a biocompatible filler material with a therapeutic agent to promote tissue regeneration and healing are provided. The biocompatible filler materials that are treated with a therapeutic agent are implanted into the abscess cavity. The biocompatible filler material provides a tissue growth scaffold, and the therapeutic agent enhances tissue growth and healing. 1. A method for treating a fistula of a mammal , said method comprising:(a) obtaining a synthetic, bioabsorbable, non-woven material that is configured for implantation into the fistula,(b) soaking the material in a solution comprising adipose-derived stem cells and platelet derivative material for from about 1 hour to about 5 days, wherein the adipose-derived stem cells and platelet derivative material impregnate the material, thereby forming a treated material, and(c) implanting the treated material into the fistula.2. The method of claim 1 , wherein said mammal is a human.35-. (canceled)6. The method of claim 1 , wherein said fistula is an anal fistula.78-. (canceled)9. The method of claim 1 , wherein said soaking step comprises soaking the material in said solution for from about 18 hours to about 5 days.10. The method of claim 1 , wherein said soaking step comprises soaking the material in said solution for from about 1 day to about 5 days.11. The method of claim 1 , wherein said soaking step comprises soaking the material in said solution for from about 3 days to about 5 days. This application is a divisional of U.S. Ser. No. 14/435,778, filed Apr. 15, 2015, which is a National Stage application under 35 U.S.C. § 371 of International Application No. PCT/US2013/065631, having and International Filing Date of Oct. 18, 2013, which a claims the benefit of U.S. Provisional Application Ser. No. 61/715,506, filed Oct. 18, 2012. The disclosures of the prior applications are ...

COMPRESSION RESISTANT IMPLANTS INCLUDING AN OXYSTEROL AND METHODS OF USE

Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth, the compression resistant implant comprising porous ceramic particles in a biodegradable polymer, and an oxysterol disposed in or on the compression resistant implant. Methods of making and use are further provided. 1. A compression resistant implant configured to fit at or near a bone defect to promote bone growth , the compression resistant implant comprising porous ceramic particles in an amount of about 30 wt % to about 99.5 wt % in a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % based on a total weight of the implant , and an oxysterol disposed in or on the compression resistant implant.2. An implant according to claim 1 , wherein the implant is not compressed any more than about 20% in any one direction for a period of at least about 30 days in vivo.3. An implant according to claim 1 , wherein (i) the porous ceramic particles are uniformly distributed throughout the implant; (ii) the oxysterol is uniformly distributed throughout the biodegradable polymer; and/or (iii) the oxysterol is uniformly distributed throughout the porous ceramic particles.4. An implant according to claim 1 , wherein the porous ceramic particles form a ceramic skeleton claim 1 , the skeleton having pores in the range of 1-10 mm in diameter claim 1 , and a total porosity of 50-98%.5. An implant according to claim 1 , wherein the implant comprises autograft claim 1 , allograft and/or xenograft bone particles.6. An implant according to claim 1 , wherein the biodegradable polymer comprises porcine-derived collagen claim 1 , human-derived collagen claim 1 , bovine-derived collagen claim 1 , piscine-derived collagen claim 1 , ovine-derived collagen claim 1 , recombinant collagen claim 1 , gelatin claim 1 , or combinations thereof.7. An implant according to claim 1 , wherein (i) the porous ceramic particles comprise bone powder claim 1 , demineralized bone ...

Implants having a high drug load of an oxysterol and methods of use

Provided is an implant configured to fit at or near a bone defect to promote bone growth, the implant comprising: a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and an oxysterol in an amount of about 20 wt % to about 90 wt % of the implant. The implant has a high oxysterol load. Methods of making and use are further provided.

TISSUE REPAIR MATERIAL

A tissue repair material includes gelatin granules, and the tissue repair material exhibits a water absorptivity of 800% by mass or more, and a residual ratio of 60% by mass or less after three hours of decomposition treatment using 1 mol/L hydrochloric acid. A block-shaped tissue repair material includes gelatin, and the block-shaped tissue repair material exhibits a water absorptivity of 800% by mass or more, and a residual ratio of 60% by mass or less after three hours of decomposition treatment using 1 mol/L hydrochloric acid. 1. A tissue repair material comprising gelatin granules , the tissue repair material exhibiting a water absorptivity of 800% by mass or more , and a residual ratio of 60% by mass or less after three hours of decomposition treatment using 1 mol/L hydrochloric acid.2. The tissue repair material according to claim 1 , wherein the gelatin granules comprise a granular gelatin that passes through a sieve having openings of 1400 μm.3. The tissue repair material according to claim 1 , wherein the gelatin granules comprise a crosslinked product of gelatin.4. The tissue repair material according to claim 1 , wherein the gelatin granules comprise a thermally crosslinked product of gelatin.5. The tissue repair material according to claim 1 , wherein the tissue repair material is granular.6. The tissue repair material according to claim 1 , wherein the gelatin granules have communicating holes having a hole diameter of from 10 μm to 2500 μm.7. The tissue repair material according to claim 1 , wherein the gelatin granules comprise a recombinant gelatin including no serine residues or threonine residues.8. The tissue repair material according to claim 1 , wherein the gelatin granules comprise a recombinant gelatin that includes no serine residues claim 1 , threonine residues claim 1 , asparagine residues claim 1 , tyrosine residues claim 1 , or cysteine residues.9. The tissue repair material according to claim 1 , wherein the gelatin granules comprise a ...

Method of Treating Scoliosis Using a Biological Implant

The present invention is a bone growth stimulating and promoting cytokine type biological implant preferably comprising PTH coated with a controlled release biodegradable coating that is implanted preferably in the concave side of a scoliotically curved spine in combination with a bone growth inhibiting type biological implant preferably comprising methotrexate or like anti-metabolite coated with a controlled release biodegradable coating that is implanted preferably in the convex side of a scoliotically curved spine. The insertion of the biological implant is highly non-invasion, especially as compared to more conventional spine surgical methods, and the biological implant does not decrease spinal mobility or spinal range of motion.

WNT COMPOSITIONS AND METHODS FOR PURIFICATION

Disclosed herein are methods, processes, compositions, and kits for generating bone graft materials for use at a site of bone defect that utilizes a composition which contains liposomal Wnt polypeptide, such as liposomal Wnt3a polypeptide, liposomal Wnt5a polypeptide, or liposomal Wnt10b polypeptide. Also disclosed herein are methods, processes, compositions, and kits for enhancing mammalian bone marrow cells that utilizes a composition which contains liposomal Wnt polypeptide, such as liposomal Wnt3a polypeptide, liposomal Wnt5a polypeptide, or liposomal Wnt10b polypeptide. 1. A composition comprising:a functionally active mammalian Wnt polypeptide; andan aqueous solution comprising liposomes, wherein the liposomes comprise a sterol lipid, and wherein the liposomes have a net charge of 0 at a pH of between about 6.5 and about 8.0.2. The composition of claim 1 , wherein the Wnt polypeptide is a mammalian Wnt3a polypeptide.3. The composition of claim 11 , wherein the mammalian Wnt3a polypeptide is a human Wnt3a polypeptide.4. The composition of claim 1 , wherein the functionally active Wnt polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:1.5. The composition of claim 1 , wherein the functionally active Wnt polypeptide comprises a lipid modification at an amino acid position corresponding to amino acid residue 209 as set forth in SEQ ID NO:1.6. The method of claim 5 , wherein the lipid modification is palmitoylation.7. The composition of claim 1 , wherein the functionally active Wnt polypeptide is not lipid modified at an amino acid position corresponding to amino acid residue 77 as set forth in SEQ ID NO:1.8. The composition of claim 1 , wherein the functionally active Wnt polypeptide is integrated into the liposomal membrane.9. The composition of claim 8 , wherein the functionally active Wnt polypeptide is not incorporated into the aqueous core of the liposomes.10. The composition of claim 1 , wherein the concentration of the functionally ...

FUNCTIONALIZATION OF BIOMATERIALS TO CONTROL REGENERATION AND INFLAMMATION RESPONSES

The inventions provided herein generally relate to compositions and methods for controlling response of immune cells to at least one stimulus or condition (e.g., but not limited to, tissue damage, an implantable device and/or a cytokine) in vitro or in vivo. The compositions described herein comprise a biomaterial (e.g., a silk fibroin-based matrix) comprising at least one immune cell-modulating agent in an effective amount sufficient to selectively alter activation state of at least one type of immune cells (e.g., but not limited to macrophages and dendritic cells). Accordingly, in some embodiments, the compositions and methods described herein can be used to selectively skew macrophages to M1 phenotype and/or M2 phenotype and thereby control the inflammatory and/or regenerative responses of the macrophages, e.g., to repair and/or regenerate a target tissue. 1. A composition comprising a biomaterial comprising at least one immune cell-modulating agent in an effective amount sufficient to selectively alter activation state of at least one type of immune cell upon contact with said at least one immune cell-modulating agent.2. The composition of claim 1 , wherein said at least one type of the immune cell is selected from the group consisting of monocytes claim 1 , macrophages claim 1 , dendritic cells claim 1 , megakaryocytes claim 1 , granulocytes claim 1 , T cells claim 1 , B cells claim 1 , natural killer (NK) cells claim 1 , and any combinations thereof.3. (canceled)4. (canceled)5. The composition of claim 1 , wherein the biomaterial is adapted for a sustained release of said at least one immune cell-modulating agent.6. The composition of claim 1 , wherein the biomaterial comprises at least two immune cell-modulating agents.7. The composition of claim 6 , wherein the biomaterial is adapted to release a first immune cell-modulating agent and a second immune cell-modulating agent at different time points.8. The composition of claim 7 , wherein the biomaterial ...

Intervertebral fusion device comprising an intervertebral stabilising screw and a composition for bone remodelling

The invention relates to an intervertebral fusion device comprising an intervertebral stabilizing screw and a composition for bone remodeling. The intervertebral stabilizing screw comprises: a main body with an axial through-hole and a distal thread that is secured to the bone, located at a distal end of the main body; a hollow proximal secondary body that can slide along the length of the main body; and a travel stop for the proximal secondary body, located on an outer surface of the main body. According to the invention, the proximal secondary body also includes an external thread for securing to the bone, and the main body comprises at least one fill hole, located between the distal thread and the travel stop, for connecting an intervertebral space to the aforementioned axial hole.

DEVICES, COMPOSITIONS AND RELATED METHODS FOR ACCELERATING AND ENHANCING BONE REPAIR

The present invention relates to novel therapeutic nanoparticles. In particular, the present invention is directed to nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) with angiogenesis-activating-agents, methods of synthesizing the same, devices or compositions comprising such nanoparticles, as well as systems and methods utilizing the nanoparticles (e.g., in therapeutic settings for enhancing and/or activating angiogenesis at targeted tissue region). 1. A device comprising a nanoparticle associated with an angiogenesis-activating-agent ,wherein associated with is selected from the group consisting of complexed, conjugated, encapsulated, absorbed, adsorbed, and admixed,wherein the nanoparticle is selected from the group consisting of hyaluronic acid nanoparticles, sHDL nanoparticles, fullerenes, endohedral metallofullerenes buckyballs, trimetallic nitride templated endohedral metallofullerenes, single-walled and multi-walled carbon nanotubes, branched and dendritic carbon nanotubes, gold nanorods, silver nanorods, single-walled and multi-walled boron/nitrate nanotubes, carbon nanotube peapods, carbon nanohorns, carbon nanohorn peapods, liposomes, nanoshells, dendrimers, any nanostructures, microstructures, or their derivatives formed using layer-by-layer processes, self-assembly processes, or polyelectrolytes, microparticles, quantum dots, superparamagnetic nanoparticles, nanorods, cellulose nanoparticles, glass and polymer micro- and nano-spheres, biodegradable PLGA micro- and nano-spheres, gold nanoparticles, silver nanoparticles, carbon nanoparticles, iron nanoparticles, carboxymethylcellulose and related mixtures, polysaccharides, polyamino acids, polyacrylates, poly-alcohols, polyesters, pluronics, pullulans, and a modified micelle,wherein the angiogenesis-activating-agent is configured to accomplish one or more of the following:increase and/or activate angiogenesis upon administration to a subject,increase HIF- ...

METHOD FOR PREPARING A SUPPLEMENT FROM MESENCHYMAL CELL CULTURES OF WHARTON'S JELLY AND USES OF SAME

A method for preparing a supplement from mesenchymal cell cultures of Wharton's jelly including factors to favor the culture growth of cells from cutaneous system, in vitro, and to methods for producing epidermal, dermal, or cutaneous equivalents, and which may also be used as supplement for the proliferation and activation of autologous fibroblasts for subsequent intradcrmal use. 1. A method for preparing of a supplement to favor the cellular proliferation in vitro of cells from a cutaneous system , the method comprises the steps of:a) cultivating mesenchymal cells of Wharton's jelly in a suitable culture medium with growth factors to reach a suitable confluence;b) harvesting the cultivated cells from step a) and further cultivating the harvested cells in a suitable medium, without growth factors, to form a conditioned medium:c) collecting the conditioned medium from step b);d) repeating steps a) and b), at least once; ande) concentrating the conditioned medium to form a concentrate and sterilizing the concentrate by filtration.2. A supplement comprising growth factors to favor the cellular proliferation in vitro of cells from the cutaneous system prepared in accordance with the method from .3. The supplement in accordance with claim 2 , wherein the supplement is configured for expansion of cutaneous cellular populations or as an addition in culture medium for the same claim 2 , wherein the supplement claim 2 , when in use claim 2 , is diluted in the culture medium to a concentration of between 5% and 50%.4. A method to favor the growth and activation in vitro of cells from cutaneous system characterized in that comprising cultivate such cells from cutaneous system in a culture medium containing the supplement in accordance with .5. The method in accordance with claim 4 , wherein the cells from cutaneous system comprise fibroblasts claim 4 , keratinocytes claim 4 , dendritic cells claim 4 , monocytes or combinations of the same.6. The method in accordance with ...

COATING DEVICE

A device for coating at least regions of a medical implant including a powder having at least one pharmaceutically active substance or one bone growth-promoting substance such that the powder can be transferred to the medical implant when the medical implant is contacted. 1. A device for coating at least regions of a medical implant , the device comprising: 'wherein the powder is transferred to the medical implant through contacting it with the medical implant.', 'a container having an opening for introduction and removal of the medical implant, the container containing a powder comprising at least one pharmaceutically active substance or one bone growth-promoting substance,'}2. The device according to claim 1 , wherein the opening is closed by a pull-off lid.3. The device according to claim 2 , further comprising a wiper arranged in a region of the opening.4. The device according to claim 3 , wherein the wiper is disc-shaped and includes at least one notch that connects a top and a bottom of the wiper.5. The device according to claim 3 , wherein the wiper is shaped as an envelope of cone or a hemispherical surface claim 3 , wherein a tip of the cone or the hemispherical surface is oriented toward the powder claim 3 , and wherein the cone or the hemispherical surface contains the at least one notch that connects the top and the bottom of the wiper.6. The device according to claim 1 , further comprising:a transfer means arranged above the powder, the transfer means being used to transfer a liquid to the medical implant, wherein the liquid is contained in the transfer means.7. The device according to claim 6 , wherein the transfer means comprises pores that contain the liquid in the form of a solution or suspension claim 6 , wherein the liquid contains a second pharmaceutically active substance.8. The device according to claim 1 , wherein the bone growth-promoting substance comprises a mixture of α- and β-calcium phosphate. This application is a divisional of U.S. ...

WOUND CARE COMPOSITIONS

Glass-based particles of a biocompatible material which comprises 40 to about 80 wt % borate (BO) intermixed into a carrier which is an ointment, cream, or surgical glue. 1. Glass-based particles of a biocompatible material intermixed into a carrier ,{'sub': 2', '3, 'wherein the glass-based particles comprise from 40 to about 80 wt % BO;'}wherein the carrier is a biocompatible ointment or cream or a surgical glue.2. The glass-based particles intermixed into a carrier of claim 1 , wherein the glass-based particles comprise one or more alkali oxides selected from the group consisting of LiO claim 1 , NaO claim 1 , KO claim 1 , and RbO claim 1 , and one or more alkaline earth oxides selected from the group consisting of MgO claim 1 , SrO claim 1 , BaO claim 1 , and CaO.3. The glass-based particles intermixed into a carrier of claim 1 , wherein the glass-based particles comprise from about 50 to about 80 wt % BO.4. The glass-based particles intermixed into a carrier of claim 1 , wherein the glass-based particles comprise from about 5 to about 20 wt % of one or more alkali oxides selected from the group consisting of LiO claim 1 , NaO claim 1 , KO claim 1 , and RbO claim 1 , and from about 5 to about 40 wt % of one or more alkaline earth oxides selected from the group consisting of MgO claim 1 , SrO claim 1 , BaO claim 1 , and CaO.5. The glass-based particles intermixed into a carrier of wherein the glass-based particles further comprise one or more trace elements selected from the group consisting of Ag claim 1 , Cu claim 1 , F claim 1 , Fe claim 1 , Mn claim 1 , Mo claim 1 , Ni claim 1 , Sr claim 1 , and Zn in a concentration between about 0.05 and 10 wt % per trace element chemically dissolved in glass.6. The glass-based particles intermixed into a carrier of wherein the glass-based particles further comprise one or more trace elements selected from the group consisting of Ag claim 4 , Cu claim 4 , F claim 4 , Fe claim 4 , Mn claim 4 , Mo claim 4 , Ni claim 4 , Sr ...

Platelet-Derived Growth Factor Compositions and Methods of Use Thereof

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

MAGNESIUM/POLYMER COMPOSITE-CONTAINING SCAFFOLDS TO ENHANCE TISSUE REGENERATION

The invention relates to magnesium-polymer composites, methods for their preparation and applications for their use. The composites include a combination of magnesium particles and polymer matrix. The polymer can include, but is not limited to, poly(lactic co-glycolic) acid. In certain embodiments, the composites of the invention are particularly useful for forming medical devices for implantation into a body of a patient. In certain other embodiments, the magnesium-polymer composites are useful for wound healing compositions for administration to an exterior surface of a body of a patient. 1. A magnesium-polymer composite for tissue healing and regeneration , comprising:magnesium particles; andpolymer matrix, wherein the magnesium particles are embedded in the polymer matrix.2. The composite of claim 1 , wherein the magnesium particles are selected from the group consisting of pure magnesium particles and powder claim 1 , magnesium alloy particles and powder claim 1 , metallic magnesium claim 1 , magnesium salt particles and powder claim 1 , and combinations thereof.3. The composite of claim 1 , wherein the polymer matrix is selected from the group consisting of calcium phosphate claim 1 , hydroxyapatite claim 1 , lecithin claim 1 , collagen claim 1 , fibrin claim 1 , gelatin claim 1 , silk claim 1 , elastin claim 1 , chitosan claim 1 , starch claim 1 , alginate claim 1 , hyaluronic acid claim 1 , chondroitin claim 1 , agarose claim 1 , cellulose claim 1 , polyester claim 1 , poly(glycolic acid) claim 1 , poly(L-lactic acid) claim 1 , poly(lactic-co-glycolic acid) claim 1 , poly(caprolactone) claim 1 , poly(propylene fumarate) claim 1 , polyorthoester claim 1 , polyanhydride claim 1 , poly(etheylene glycol) claim 1 , polycarbonate claim 1 , polyurethane claim 1 , elastomer claim 1 , poly(glycerol sebacate) claim 1 , and mixtures thereof.4. The composite of claim 1 , wherein at least one of the magnesium particles and the polymer matrix is selected such that ...

AMORPHOUS HYALURONIC ACID-MAGNESIUM/CALCIUM POLYPHOSPHATE MICROPARTICLES FOR CARTILAGE REGENERATION AND REPAIR

This invention concerns a biomimetic material based on energy-rich amorphous magnesium polyphosphate (Mg-polyP) microparticles that enhance cartilage synthesis and regeneration. One preferred formulation of the inventive material is a hyaluronic acid-Mg/Ca-polyP paste that can be produced from a water-soluble salt of polyP and water-soluble hyaluronic acid in the presence of water-insoluble/nearly insoluble calcium carbonate. Surprisingly, the inventor found that this cartilage-like material comprising amorphous Mg/Ca-polyP microparticles promotes the adhesion of chondrocytes and strongly upregulates the expression of the chondrocyte marker genes encoding alkaline phosphatase, collagen type 3A1, aggrecan and Sox9. The material through scavenging calcium ions (Mg/Ca exchange) and binding of the calcium-polyP to hyaluronic acid shows biomechanical properties, comparable to cartilage and thus can be used for prevention of calcium crystal formation in the synovial fluid and treatment of joint dysfunctions caused by osteoarthritis. 1. A method for producing a pharmaceutical composition comprising amorphous magnesium polyphosphate microparticles , wherein said method comprises the steps of:i) dissolving a soluble polyphosphate salt in an aqueous medium,ii) adding an aqueous solution of a soluble magnesium salt to said polyphosphate salt solution, andiii) collecting and drying particles formed after washing with alcohol.2. A method for producing a pharmaceutical composition comprising amorphous magnesium polyphosphate microparticles and hyaluronic acid , wherein said method comprises the steps of:i) mixing of an aqueous solution of a soluble polyphosphate salt with an aqueous solution of hyaluronic acid,ii) adding a soluble magnesium salt to the mixture from step (i), andiii) allowing said mixture to fully gelatinate.3. The method according to claim 1 , wherein said soluble polyphosphate salt is sodium polyphosphate.4. The method according to claim 1 , wherein the chain ...

BONE REPAIRING MATERIAL AND METHOD FOR PRODUCING THEREOF

A bone repairing material comprises a composition including an α-calcium sulfate hemihydrate and an autologous bone powder, wherein the bone repairing material contains 20˜60 weight percent of the autologous bone powder and 40˜80 weight percent of the α-calcium sulfate hemihydrate. The bone repairing material has a particle size in the range of 50˜1,000 μm. A method for producing the bone repairing material comprises the following steps: producing the α-calcium sulfate hemihydrate from a calcium sulfate dihydrate by microwave heating; grinding an autologous bone for generating the autologous bone powder; and, mixing the α-calcium sulfate hemihydrate and the autologous bone powder to form the bone repairing material. 1. A bone repairing material comprises a composition including an α-calcium sulfate hemihydrate and an autologous bone powder , wherein the bone repairing material contains 20˜60 weight percent of the autologous bone powder and 40˜80 weight percent of the α-calcium sulfate hemihydrate , and the bone repairing material has a particle size in the range of 50˜1 ,000 μm.2. A method for producing the bone repairing material of claim 1 , comprising the following steps:producing the α-calcium sulfate hemihydrate from a calcium sulfate dihydrate by microwave heating;grinding an autologous bone for generating the autologous bone powder; andmixing the α-calcium sulfate hemihydrate and the autologous bone powder to form the bone repairing material.3. The method for producing the bone repairing material of claim 2 , wherein the step of mixing the α-calcium sulfate hemihydrate and the autologous bone powder to form the bone repairing material further comprises the following substeps:taking the autologous bone powder and the α-calcium sulfate hemihydrate into a stirring device and stirring for a first predetermined time, wherein the autologous bone powder is accounted for 20˜60 weight percent of the bone repairing material and the α-calcium sulfate hemihydrate is ...

SETTING OF HARDENABLE BONE SUBSTITUTE

The invention relates to hardenable ceramic bone substitute compositions having improved setting, powders for such compositions and methods for their manufacture and use in medical treatment. More specifically the invention relates to hardenable bone substitute powder and hardenable bone substitute paste with improved setting properties, comprising calcium sulfate and heat-treated hydroxyapatite (passivated HA), which bone substitute is suitable for treatment of disorders of supportive tissue such as bone loss, bone fracture, bone trauma and osteomyelitis.

A NANOBIOCOMPOSITE FORMULATION FOR WOUND HEALING AND A PROCESS FOR THE PREPARATION THEREOF

The present invention involves the isolation of plant based CNCs from the leaves of . For the formation of NCs, a novel greener approach using LE as reducing agent for in situ impregnation of AgNPs as fillers into CNCs as matrix is reported. The silver nitrate solution in three different concentrations of 1 mM, 5 mM and 10 mM was used to form NCs where AgNPs have been incorporated into CNCs matrix. The CNCs and NCs were characterized using SEM, TEM, XRD, Zeta potential, FT-IR, and UV-Vis spectroscopy. NCs developed in the form of film and ointment showed strong antimicrobial activity against both gram negative and gram positive bacteria. NCs wound dressing is capable of regulating wound exudates and providing moisture to wound responsible for faster healing of acute wounds. The observations from histopathological and biochemical assays confirmed that NCs enhance healing because of lesser inflammation, rapid angiogenesis, early collagen formation and enhanced rate of reepithelization. 1Syzygium cumini. A nanobiocomposite formulation (NCs) in ointment form comprising silver nanoparticles (AgNPs) and cellulose nanocrystals (CNCs) wherein the ratio of AgNPs and CNCs is in the range of 0.067%-0.4% w/w AgNPs: 7-8% w/w CNCs , and wherein the cellulose is derived from leaves.2. A process for the preparation of the nanobiocomposite formulation in ointment form as claimed in claim 1 , the method comprising:{'i': 'Syzygium cumini', 'a) treating washed and dried leaves with bleaching agent at pH in the range of 3.0-4.0 for a time period ranging between 2-3 h at a temperature ranging between 70-100° C. to obtain a bleached fibrous material;'}b) filtering and washing the bleached fibrous material as obtained from (a) followed by treating with acidified bleaching agent solution at a temperature ranging between 22-30° C. for a time period ranging 16-18 h to obtain acidified fibrous material;c) washing the acidified fibrous material as obtained from (b) followed by keeping it into 2 ...

Preparation method of injectable thermosensitive chitosan/tempo based-oxidized cellulose hydrogel

The present invention provides a method for preparing an injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel. The injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel exhibits superior biocompatibility through addition of TEMPO-oxidized cellulose nanofibers, and excellent cell proliferation and bone regeneration through cellular interaction, and is gelled in vivo, thus being highly useful as a filler for wound healing and bone regeneration. In addition, the injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel exhibits excellent porosity, has an interconnected structure and is thermogelling, based on thermosensitivity of undergoing a sol-gel transition depending on temperature, thus inducing rapid gelation in vivo and facilitating bone regeneration upon implantation in vivo.

FOAMED BIOCOMPATIBLE MATERIALS FOR TISSUE REPAIR

A foamed biocompatible material for use in tissue repair and a kit for producing same. The kit includes a container having a valve and an inlet, and a tissue-repair composition containing a biocompatible material and a liquid carrier, in which the composition is placed in the inlet of the container and the inside of container has a pressure lower than that of the outside so that, upon opening the valve, the composition is forced into the container by the pressure difference to form a foam inside the container. Also disclosed is a method of preparing a foamed biocompatible material for tissue repair. 1. A foamed biocompatible material produced by a method comprising:providing a container configured to sustain a high pressure such that the container has an internal pressure of greater than 1 atm and less than 250 atm, wherein the container includes a valve, a nozzle, and a tissue-repair composition containing a s neutralized and homogeneous solution at pH 6-8 that includes a biocompatible material, wherein the biocompatible material consists of collagen at a concentration of 1%-10%, a liquid carrier that is water, physiological saline, or phosphate buffered saline, and a gas that is air, oxygen, nitrogen, or carbon dioxide; andopening the valve to release from the nozzle a foam formed of the tissue-repair to composition.2. The foamed biocompatible material of claim 1 , wherein the biocompatible material is not cross-linked3. The foamed biocompatible material of claim 1 , wherein the biocompatible material is a polypeptide claim 1 , a polysaccharide claim 1 , or a combination thereof.4. The foamed biocompatible material of claim 3 , wherein the biocompatible material is collagen claim 3 , hyaluronic acid claim 3 , or a combination thereof.5. The foamed biocompatible material of claim 1 , wherein the foamed biocompatible material has pores less than 250 μm in diameter and a pore density higher than 70%.6. The foamed biocompatible material of claim 5 , wherein the ...

BIODEGRADABLE POLYMERIC FILM INCLUDING EXTRACELLULAR MATRIX AND USE THEREOF

Provided are a biodegradable polymeric film including an extracellular matrix, and use thereof, and particularly, a method of producing a poly(lactide-co-ε-caprolactone) film including an extracellular matrix, a film produced by the method, and an ophthalmic material including the film. 1. A method of producing a poly(lactide-co-ε-caprolactone) film comprising an extracellular matrix , the method comprising:producing a two-phase mixture comprising poly(lactide-co-ε-caprolactone) and an extracellular matrix by adding a poly(lactide-co-ε-caprolactone)(PLCL) polymer solution to a solid-phase substrate to which the extracellular matrix (ECM) is attached; andforming a PLCL-ECM film on a surface of the solid-phase substrate by evaporating the solvent from the produced two-phase mixture,wherein the PLCL-ECM film is formed by physical crosslinking between the PLCL and the ECM.2. The method of claim 1 , wherein the ECM is obtained through decellularization of a biological tissue or a cultured cell layer.3. The method of claim 1 , wherein the ECM is obtained through decellularization of a cultured fibroblast cell layer.4. The method of claim 1 , wherein a molecular weight of the PLCL is 100 kDa to 200 kDa.5. The method of claim 1 , wherein the PLCL solution comprises claim 1 , as the solvent claim 1 , chloroform claim 1 , tetrahydrofuran claim 1 , hexafluoroisopropanol claim 1 , dimethylformamide claim 1 , acetone claim 1 , dimethyl sulfoxide claim 1 , distilled water claim 1 , a phosphate buffered solution (PBS) claim 1 , or saline.6. The method of claim 1 , wherein the PLCL solution has a concentration of 0.5% (w/v) to 5% (w/v).7. The method of claim 1 , wherein the evaporating of the solvent is carried out at 5° C. to 60° C.8. The method of claim 7 , wherein the evaporating of the solvent is carried out for 12 hr to 72 hr.9. The method of claim 1 , further comprising separating the PLCL-ECM film from the surface of the solid-phase substrate.10. A poly(lactide-co-ε- ...

Methods and Compositions for Promoting Wound Healing

The present invention provides methods and compositions that use the combination of Tris and EDTA to inhibit the growth of microorganisms at the site of a wound or burn, and/or to promote the healing of a wound or burn, and/or to reduce the sensation of pain at the site of a wound or burn. The amount of Tris and EDTA applied to a wound or burn can be selected to achieve one or more of the foregoing effects. 180-. (canceled)81. A composition consisting of Tris , EDTA , and dissolved silver in a pharmaceutically acceptable carrier selected from the group consisting of water , saline , physiological saline , an ointment , a cream , an oil-water emulsion , and a gel , wherein the Tris , EDTA , and dissolved silver are in amounts sufficient to promote healing of a burn on a mammalian , bird , or reptile body , the composition consisting of a pH of from 6.0 to 9.0 , and optionally , a detergent , a vitamin , an anti-inflammatory agent , lecithin , glycerin , methyl paraben , aloe vera , polypropylene glycol ethoxylate , and/or poloxamer 407.82. The composition according to wherein the detergent is from 1% to 30% of the composition by volume/volume.83. The composition according to wherein the silver is at a concentration of from 1 ppm to 300 ppm.84. The composition according to wherein the silver is at a concentration of from 1 ppm to 50 ppm.85. The composition according to wherein the EDTA is at a concentration of from 1 mM to 250 mM.86. The composition according to wherein the Tris is at a concentration of from 10 mM to 250 mM.87. A composition consisting of Tris claim 81 , EDTA claim 81 , and dissolved silver in a pharmaceutically acceptable carrier selected from the group consisting of water claim 81 , saline claim 81 , physiological saline claim 81 , an ointment claim 81 , a cream claim 81 , an oil-water emulsion claim 81 , and a gel claim 81 , wherein the Tris claim 81 , EDTA claim 81 , and dissolved silver are in amounts sufficient to promote healing of a wound on a ...

CELL-BASED COMPOSITIONS, CELL-BASED BANDAGE DEVICES AND SYSTEMS AND METHODS OF TREATMENT THEREWITH

A composition includes a biodegradable matrix, cells within the biodegradable matrix and at least one bioactive agent having limited mobility relative to the cells within the biodegradable matrix. The at least one bioactive agent is bioactive within the biodegradable matrix for regulation of the cells to enhance cell survival. 1. A composition comprising a biodegradable matrix , cells within the biodegradable matrix and at least one bioactive agent having limited mobility relative to the cells within the biodegradable matrix , wherein the at least one bioactive agent is bioactive within the biodegradable matrix for regulation of the cells to enhance cell survival.2. The composition of wherein the at least one bioactive agent is a matrikine or a matrikine fragment which is immobilized upon the cells or is immobilized within the biodegradable matrix.3. The composition of wherein the at least one bioactive agent is a matrikine or a matrikine fragment.4. The composition of wherein the cells are cells which can differentiate into at least one other cell type.5. The composition of wherein the cells are multipotent.6. The composition of wherein the cells include at least one of mesenchymal stem cells claim 4 , tissue stromal cells claim 4 , tissue epithelial cells or endothelial progenitor cells.7. The composition of further comprising cells or another agent that facilitates or directs differentiation.8. The composition of wherein the matrikine or the matrikine fragment is tethered to the biodegradable matrix.9. The composition of wherein the matrikine or the matrikine fragment is covalently bonded to the biodegradable matrix.10. The composition of wherein the matrikine or the matrikine fragment is non-covalently bonded to the biodegradable matrix.114. The composition of wherein the matrikine or the matrikine fragment is adhered to the cells.12. The composition of wherein the matrikine or the matrikine fragment is selected from the group of a tenascin claim 4 , a laminin ...

HEMOSTATIC COMPOSITIONS AND METHODS OF MAKING AND USING SAME

The disclosure pertains to hemostatic compositions comprising a plurality of nonwoven fibers disposed in a rapidly soluble solid matrix and methods of making and using the same. The compositions may also comprise one or more therapeutic agents. 1. A hemostatic composition comprising: a plurality of nonwoven fibers; a rapidly soluble solid matrix; and one or more therapeutic agents. This application is a continuation of U.S. application Ser. No. 12/872,308, filed Aug. 31, 2010.Heart and vascular disease are major problems in the United States and throughout the world. Conditions such as atherosclerosis result in blood vessels becoming blocked or narrowed. This blockage can result in lack of oxygenation of the heart, which has significant consequences because the heart muscle must be well oxygenated in order to maintain its blood pumping action.Occluded, stenotic, or narrowed blood vessels may be treated with a number of relatively non-invasive medical procedures including percutaneous transluminal angioplasty (PTA), percutaneous transluminal coronary angioplasty (PTCA), and atherectomy. Angioplasty techniques typically involve the use of a balloon catheter. The balloon catheter is advanced over a guidewire such that the balloon is positioned adjacent a stenotic lesion. The balloon is then inflated and the restriction of the vessel is opened. During an atherectomy procedure, the stenotic lesion may be mechanically cut away from the blood vessel wall using an atherectomy catheter.The non-invasive medical procedures identified above typically gain access to the vasculature through an opening formed in the femoral artery. For obvious reasons, once the procedure is completed the opening in the femoral artery will need to be closed. This may include applying direct pressure at the wound site. Alternatively, a device may be used to assist in the closing of the artery.A wide variety of medical devices have been developed for medical use, for example, use in non-invasive ...

Class of Anti-Adhesion Hydrogels With Healing Aspects

Disclosed are hydrogels polymerized with a biofunctional moiety, biodegradable and permanent, designed to be implantable in a mammalian body and intended to block or mitigate the formation of tissue adhesions. The hydrogels of the present invention are characterized by comprising four structural elements: a) a polymeric backbone which defines the overall polymeric morphology, b) linkage groups, c) side chains, and d) biofunctional end groups. The hydrophobicity of the various structural elements are chosen to reduce tissue adhesion and enhance the biofunctional aspect of the end groups. The morphology of these polymers are typically of high molecular weight and have shape to encourage entanglement. Useful structures include branching chains, comb or brush, and dendritic morphologies.

ACELLULAR SOFT TISSUE-DERIVED MATRICES AND METHODS FOR PREPARING SAME

A composition including delipidated, decellularized adipose tissue and delipidated, decellularized fascial tissue is provided. The composition may further include exogenous tissuegenic cells, an exogenous growth-inductive substance, and/or a carrier. The composition is suitable for implantation into a living body in plastic surgery procedures, including reconstructive or cosmetic surgery procedures, wound care procedures or other procedures of regenerative medicine. A method of preparing an acellular soft tissue-derived matrix from adipose tissue and fascial tissue is also provided. The method involves preparing a delipidated, decellularized adipose-derived matrix by delipidizing the adipose tissue and decellularizing the adipose tissue; preparing a delipidated, decellularized fascia-derived matrix by delipidizing the fascial tissue and decellularizing the fascial tissue; and combining the delipidated, decellularized adipose-derived matrix and the delipidated, decellularized fascia-derived matrix to produce said acellular soft tissue-derived matrix. The resulting Acellular soft tissue-derived matrix may be partially dried, substantially dried, or not dried. 1. A composition , comprising delipidated , decellularized adipose tissue and delipidated , decellularized fascial tissue.2. The composition of claim 1 , wherein said delipidated claim 1 , decellularized adipose tissue is substantially free of native nucleic acids claim 1 , or said delipidated claim 1 , decellularized fascial tissue is substantially free of native nucleic acids claim 1 , or both.3. The composition of claim 1 , further comprising exogenous tissuegenic cells.4. The composition of claim 1 , further comprising at least one exogenous growth-inductive substance.5. The composition of claim 1 , further comprising a carrier.6. The composition of claim 5 , wherein said carrier comprises a substance selected from the group consisting of an isotonic solution claim 5 , a sodium chloride solution claim 5 , a ...

BONE DEFECT FILLING MATERIAL, AND PRODUCTION METHOD THEREFOR

Rebuilding a defected bone by activating the innate self-regeneration ability of bone requires a considerably long period of time. The purpose of the present invention is to provide a bone defect filling material that initiates a bone rebuilding activity as quickly as possible after implantation and thereafter remains in the defect to continue promoting bone formation activity until sufficient bone formation has been achieved for the rebuilding of the defect. The present invention provides a cotton-like bone defect filling material comprising biodegradable fibers produced by electrospinning. The biodegradable fibers contain 40-60 wt % of calcium phosphate particles and 10 wt % or more of silicon-releasing calcium carbonate particles, with the remainder containing 30 wt % or more of poly(L-lactic acid) polymer, and the amount of the poly(L-lactic acid) polymer that is non-crystalline is 75-98%. 1. A material for filling a bone defect comprising a biodegradable fiber produced by electrospinning ,wherein the biodegradable fiber comprises silicon-releasing calcium carbonate particles, calcium phosphate particles, and a biodegradable polymer having a poly lactic acid structure having a carboxyl group at an end of a molecule of the polymer,wherein the biodegradable fiber is produced by electrospinning a spinning solution that was prepared by dissolving a composite produced by kneading the biodegradable polymer, the silicon releasing calcium carbonate particles and the calcium phosphate particles by using a solvent, andwherein the silicon releasing calcium carbonate particles and the calcium phosphate particles are distributed in the biodegradable fiber in a state that siloxane of the silicon releasing calcium carbonate particles is amide-bonded with the carboxyl group of the biodegradable polymer, and the calcium phosphate particles are not amide-bonded with the biodegradable polymer.2. The material according to claim 1 , wherein the biodegradable polymer having a poly ...

METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS

Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit. 1. (canceled)2. A method of treating a cartilage defect in subject in need thereof , comprising:identifying a subject with a cartilage defect; andadministering a therapeutically effective amount of a concentrated population of adipose-derived regenerative cells comprising stem cells to said subject sufficient to accelerate the healing of cartilage defect.3. The method of claim 2 , wherein the concentrated population of adipose-derived regenerative cells comprising stem cells has not been cultured.4. The method of claim 2 , wherein the concentrated population of adipose-derived regenerative cells comprising stem cells is obtained from adipose tissue of the subject to whom the cells are administered.5. The method of claim 2 , wherein said cartilage defect comprises osteoarthritis.6. The method of claim 2 , wherein said cartilage defect is a defect in the articular cartilage.7. The method of claim 2 , wherein said cartilage defect is a defect in the meniscal fibrocartilage.8. The method of claim 2 , wherein said cartilage defect is a defect in the knee.9. The method of claim 2 , wherein said administration step comprises administering multiple doses of said concentrated population of adipose-derived regenerative cells comprising stem cells.10. The method of claim 2 , further comprising: a tissue ...

ALIGNED NANOFIBROUS STRUCTURES FOR AXONAL REGENERATION AFTER SPINAL CORD INJURY OR SURGERY

Embodiments of the present disclosure provide for aligned nanofibrous polymer matrix structure, structures incorporating aligned nanofibrous polymer matrix structures, methods of using aligned nanofibrous polymer matrix structures, methods of making aligned nanofibrous polymer matrix structures, and the like. 1. A structure , comprising:a nanofiber hollow structure, wherein at least one type of aligned nanofibrous polymer matrix structure is disposed in the nanofiber hollow structure, each aligned nanofibrous polymer matrix structure having a distal end and a proximal end, wherein the aligned nanofibrous polymer matrix structure includes a plurality of aligned nanofibers, wherein the matrix structure encapsulates at least one component, wherein the component has a gradient-molecular orientation along the fiber-axis of the matrix structure, wherein the molecular orientation is greater at the distal end of the aligned nanofibrous polymer matrix structure and decreases along the length of the aligned nanofibrous polymer matrix structure moving towards the proximal end, wherein the gradient-molecular orientation of the components modulates the release kinetics of the components.2. The structure of claim 1 , wherein the nanofiber hollow structure is made of a polymer selected from the group consisting of: poly(lactide-co-glycolide) (PLGA) claim 1 , poly(caprolactone) (PCL) claim 1 , polydioxanone (PDO) claim 1 , poly(ester urethane urea) claim 1 , and a combination thereof; and wherein the nanofibers of the aligned nanofibrous polymer matrix structure are made of a polymer selected from the group consisting of: poly(lactide-co-glycolide) poly(lactide) (PLA) claim 1 , (PLGA) claim 1 , poly(caprolactone) (PCL) claim 1 , polylacide-co-caprolactone (PLCL) claim 1 , a polyhydroxy esters claim 1 , collagen claim 1 , gelatin claim 1 , laminin claim 1 , chitosan claim 1 , silk claim 1 , resilin claim 1 , and a combination thereof.3. (canceled)4. The structure of claim 1 , ...

NEW USE OF STEM CELL GENERATOR IN PREPARATION OF BONE DEFECT REPAIR MATERIALS

Disclosed is a new use of a stem cell generator in preparation of bone defect repair materials, wherein the stem cell generator is formed by implanting a biomaterial with osteogenic induction capability or a biomaterial loaded with active substances and/or cells into an animal or a human body and generating organoids after development, the active substances are bone morphogenetic protein-2, or bone morphogenetic protein-7, other growth factors/polypeptides having bone regeneration induction ability, growth factors/polypeptide combinations, or a combination thereof. The cells are bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells or other derived mesenchymal stem cells; other types of cells with osteogenic differentiation capability; cells that aid in osteogenic differentiation of mesenchymal stem cells, such as vascular endothelial cells and the like. The stem cell generator is used to prepare bone repair materials for treatment of various types of bone defects or bone deformities that are spontaneous or caused by trauma. 1. A stem cell generator , wherein the stem cell generator is formed by implanting a biomaterial with osteoinductive ability or a biomaterial loaded with an active substance and/or cell into an animal or human body to develop and generate an organoid , wherein the active substance is bone morphogenetic protein-2 , bone morphogenetic protein-7 , other growth factor/polypeptide having the ability to induce bone regeneration , growth factor/polypeptide combination , or a combination thereof; the cell is mesenchymal stem cell , and the mesenchymal stem cell is bone marrow-derived mesenchymal stem cell , adipose-derived mesenchymal stem cell , or mesenchymal stem cell from other sources; other type of cell having osteogenic differentiation ability; a cell assisting mesenchymal stem cell in osteogenic differentiation , such as vascular endothelial cell and the like.2. The stem cell generator of claim 1 , wherein the ...

FORMATION OF SEMI-PERMEABLE POROUS ARTIFICIAL SCAB

Porous semi-permeable artificial self-attaching scab designed to protect the eroded or injured surfaces. It can be applied on any living being (including plants). The polymerized mesh of the scab is formed when applied on the injured area by a process in which the lysed cells release enzymes that catalyze the reaction. Under this protective surface, the growth of new normal cells that can breathe freely without drying up is promoted. As a result, loss of water, proteins and electrolytes can be avoided; infections can be prevented; and the use of dressing and gauze bandage can be eliminated since they harm the new skin removed. The aqueous thixotropic red-colored fluid applied by brushing or spraying was obtained as a result of the reaction occurred in the container by the combination of the following substances: azosulfamide 1% to 5%+gentian violet 0.004% to 0.007%+dexamethasone 0.001% to 0.003′%+pantothenyl alcohol 0.5% to 2%+gentamicin 0.03% to 0.06%. 1. A fluid that forms an artificial scab , comprising:1-5 weight % of azosulfamide;0.004-0.007 weight % of gentian violet;0.001-0.003 weight % of dexamethasone;0.5-2 weight % of panthenol; and0.03-0.06 weight % of gentamycin, wherein the azosulfamide, gentian violet, dexamethasone, panthenol, and gentamycin are mixed together to form an aqueous thixotropic fluid and the aqueous fluid forms an artificial scab when applied to damaged human tissue.2. The fluid that forms an artificial scab of claim 1 , further comprising a three dimensional web formed by a reaction after the application of the aqueous fluid to the damaged human tissue.3. The fluid that forms an artificial scab of claim 1 , wherein the web comprises a plurality of ionic and covalent bonds generated by the reaction after the application of the aqueous fluid to the damaged human tissue.4. The fluid that forms an artificial scab of claim 1 , wherein the artificial scab is three dimensional.5. The fluid that forms an artificial scab of claim 1 , the ...

Polycarbonate Containing Compounds and Methods Related Thereto

Disclosed herein are crosslinked polycarbonates, composition thereof and methods thereof. The crosslinked polycarbonates can be prepared from allyl or epoxy polycarbonates. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. 122-. (canceled)23. A method of crosslinking polycarbonates , comprising:(a) providing an epoxy functionalized polycarbonate;(b) providing an allyl functionalized polycarbonate; and(c) crosslinking the epoxy functionalized polycarbonate and the allyl functionalized polycarbonate via a crosslinker.24. The method of claim 23 , wherein the crosslinker comprises one or more ether bonds.25. The method of claim 23 , wherein the crosslinker comprises at least one amine moiety.26. The method of claim 23 , wherein the crosslinker comprises at least one thiol moiety.27. The method of claim 23 , wherein the crosslinker comprises at least one amine moiety and at least one thiol moiety.34. The method of claim 23 , wherein the crosslinking thereby forms a nanoparticle.35. A method of crosslinking polycarbonates claim 23 , comprising:(a) providing a first carbonate and a second carbonate; and(b) crosslinking the first carbonate and the second carbonate via a crosslinker having a thiol moiety and an amine moiety.36. The method of claim 35 , wherein the first carbonate is an epoxy functionalized carbonate.39. The method of claim 35 , wherein the first carbonate is an allyl functionalized carbonate.42. The method of claim 35 , wherein the crosslinking thereby forms a nanoparticle. This Application is a continuation of U.S. application Ser. No. 16/422,700, filed May 24, 2019, which is a continuation of U.S. application Ser. No. 15/443,456, filed Feb. 27, 2017, now U.S. Pat. No. 10,308,774, which is a continuation of U.S. application Ser. No. 14/399,920, filed Nov. 7, 2014, now U.S. Pat. No. 9,580,548, which is a National Stage of International Application No. PCT/ ...

POLYMERIC BIOMATERIALS DERIVED FROM PHENOLIC MONOMERS AND THEIR MEDICAL USES

Disclosed are new classes of diphenol compounds, derived from tyrosol or tyrosol analogues and hydroxybenzoic acid, which are useful as monomers for preparation of biocompatible polymers. Also disclosed are biocompatible polymers prepared from these monomeric diphenol compounds, including novel biodegradable and/or bioresorbable polymers of formula. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic compositions. The invention also provides methods for preparing these monomeric diphenol compounds and biocompatible polymers. 9. The biocompatible polymer of claim 7 , wherein the phenyl groups of the recurring unit have the phenolic oxygens in the para-position.10. The biocompatible polymer of claim 7 , wherein Lis a bond claim 7 , Lis oxygen claim 7 , and Qand Zare both hydrogen.13. The biocompatible polymer of claim 11 , wherein Xand Xare iodine claim 11 , and at least one of y1 and y2 is non-zero.14. The biocompatible polymer of claim 11 , wherein Xand Xare iodine claim 11 , at least one of y1 and y2 is 2 claim 11 , and the phenyl groups of the recurring unit have the phenolic oxygens in the para-position.15. The biocompatible polymer of claim 11 , which is a polycarbonate and further comprises a second recurring unit of optionally iodinated tyrosol.16. A biocompatible polyurethane comprising an optionally iodinated tyrosine or an optionally iodinated tyrosine ester recurring unit claim 11 , and a second recurring unit selected from the group consisting of HBA (hydroxybenzoic acid) claim 11 , mono-iodinated HBA and di-iodinated HBA.28. The diphenol compound of claim 26 , wherein Lis a bond.29. The diphenol compound of claim 26 , wherein Land Lare each a bond claim 26 , Lis oxygen claim 26 , Zis hydrogen and Qis hydrogen.30. The diphenol compound of claim 26 , wherein Land Lare each a bond claim 26 , Lis ...

INTESTINAL TISSUE ENHANCED WITH THERAPEUTIC SALTS

The present invention is product and method for treating wounds, or enhancing wound healing, by contacting the wound with biomaterial or tissue that has been treated with a boron and copper composition. 1. A method of treating biomaterial comprising contacting the biomaterial with a treatment composition comprising a source of boron ions and a source of copper ions.2. The method of wherein the source of boron ions comprises up to about 80% of the composition.3. The method of wherein the source of copper ions comprises up to about 5% of the composition.4. The method of wherein the treatment composition further comprises one or more of the following ingredients: a source of calcium; a source of potassium; a source a magnesium; a source of sodium; a source of phosphorus; ionic forms or any of the above; oxide forms of any of the above; a source of strontium; a source of zinc; a source of iron; ionic forms of strontium claim 1 , zinc claim 1 , or iron; oxide forms of strontium claim 1 , zinc claim 1 , or iron; and any of the ingredients listed above alone or in any combination.5. The method of wherein the treatment composition comprises a boron oxide and a copper oxide; and further comprises at least one of an oxide of calcium claim 1 , potassium claim 1 , magnesium claim 1 , sodium claim 1 , or phosphorus.6. The method of wherein the treatment composition is an electrolyte composition.7. The method of wherein the biomaterial is selected from the group consisting of an ECM-containing material; submucosa tissues; renal capsule membrane; amnion; dura matter; pericardium; serosa; and peritoneum or basement membrane.8. The method of wherein the biomaterial is intestinal submucosa.9. The method of wherein the biomaterial is small intestine submucosa.10. The method of wherein the biomaterial is derived from an animal or human source.11. The method of wherein the biomaterial is contacted with an antimicrobial composition prior to contact with the treatment composition.12. A ...

TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE NANOFIBERS

Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of various diseases, in particular, diseases associated with decreased tensile strength of tissue, decreased elasticity of tissue, increased collagen content or abnormal collagen content in tissue, abnormal alignment of collagen in tissue, and/or increased myofibroblast content in tissue. 1. A method for treating or preventing wrinkles or depressions in the skin's surface in a human subject , comprising administering a composition comprising sNAG nanofibers to the human subject , wherein more than 50% of the sNAG nanofibers are between about 1 to 15 μm in length.2. The method of claim 1 , which is a method for treating wrinkles or depressions in the skin's surface claim 1 , wherein the human subject has wrinkles or depressions in an area on the skin's surface claim 1 , and wherein the composition is administered to the area.3. The method of or claim 1 , wherein the composition is administered topically.4. The method of claim 2 , wherein the composition is administered by local injection into the area under the skin's surface claim 2 , and wherein the local injection is an intradermal injection claim 2 , subcutaneous injection or an intramuscular injection.5. A method for regenerating a tissue or adding volume to a tissue in a human subject claim 2 , comprising administering a composition comprising sNAG nanofibers to the tissue in the human subject claim 2 , wherein more than 50% of the sNAG nanofibers are between about 1 to 15 μm in length.6. The method of claim 5 , wherein the administering is performed by local injection into the tissue claim 5 , and wherein the local injection is an intradermal injection claim 5 , subcutaneous injection or an intramuscular injection.7. A method for reducing scarring claim 5 , reducing fibrosis or reducing adhesions associated with a wound in a ...

Methods And Compositions For The Treatment Of Open And Closed Wound Spinal Cord Injuries

Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes that may be used for the treatment of spinal cord injuries. In addition, other embodiments are directed to polymeric “fill-in” bandages that may be used for the treatment of spinal cord injuries. For example, an erodible, or biodegradable, form of biocompatible polymer of the present invention is fabricated for surgical implantation into the site of the spinal cord injury. 1. A biodegradable and/or bioabsorbable polymeric tubular article suitable for treating a spinal cord injury in an animal , wherein the article comprises a biodegradable and/or bioabsorbable linear aliphatic polyester.2. The polymeric tubular article of claim 1 , wherein the linear aliphatic polyester is a polyglycolide or a copolymer poly(glycolide-co-lactide).3. The polymeric tubular article of claim 1 , comprising poly(lactic-co-glycolic acid).4. The polymeric tubular article of claim 1 , comprising poly(lactic-co-glycolic acid)-polylysine.5. The polymeric tubular article of claim 1 , comprising a blend of (1) poly(lactic-co-glycolic acid) and (2) a block copolymer of poly(lactic-co-glycolic acid)-polylysine.6. The polymeric tubular article of claim 1 , comprising a 50:50 blend of (1) poly(lactic-co-glycolic acid) and (2) a block copolymer of poly(lactic-co-glycolic acid)-polylysine.7. The polymeric tubular article of claim 6 , wherein the (1) poly(lactic-co-glycolic acid) is 75% poly(lactic-co-glycolic acid) and has an average molecular weight of Mn ˜40 claim 6 ,000.8. The polymeric tubular article of claim 6 , wherein the (2) block copolymer of poly(lactic-co-glycolic acid)-polylysine is 25% poly(lactic-co-glycolic acid)-polylysine copolymer and ...

IRRIGATION RESISTANT COMPOSITIONS FOR REGENERATION OF HARD TISSUES AND METHODS AND KITS OF USING THE SAME

An irrigation resistant bone repair composition including a biocompatible or bioactive bone repair material and a mixture of non-random poly(oxyalkylene) block copolymers is described. Also, methods for treating a bone having a bone gap or a bone defect with the composition including a biocompatible or bioactive bone repair material and a mixture of non-random poly(oxyalkylene) block copolymers are also provided. Also, kits including the irrigation resistant bone repair composition including a biocompatible or bioactive bone repair material and a mixture of non-random poly(oxyalkylene) block copolymers are described. 1. An irrigation resistant bone repair composition comprising:a biocompatible or bioactive bone repair material, and a mixture of at least one non-random poly(oxyalkylene) block copolymer and at least one non-ionic surfactant other than a non-random poly(oxyalkylene) block copolymer.2. The bone repair composition of claim 1 , wherein the poly(oxyalkylene) block copolymer is a poloxamer polymer.3. The bone repair composition of claim 1 , wherein the poly(oxyalkylene) block copolymer is selected from the group consisting of poloxamer 407 claim 1 , poloxamer 124 claim 1 , poloxamers 188 claim 1 , poloxamer 237 claim 1 , and poloxamer 338.4. The bone repair composition of claim 1 , wherein the weight ratio of the mixture is 1%-99% relative to the weight of the bone repair composition.5. The bone repair composition of claim 1 , wherein the weight ratio of the mixture is 1%-20% relative to the weight of the bone repair composition.6. The bone repair composition of claim 1 , wherein the weight ratio of the mixture is 20%-30% relative to the weight of the bone repair composition.7. The bone repair composition of claim 1 , wherein the weight ratio of the mixture is 30%-40% relative to the weight of the bone repair composition.8. The bone repair composition of claim 1 , wherein the weight ratio of the mixture is 40%-50% relative to the weight of the bone repair ...

PEPTIDE-ALBUMIN HYDROGEL PROPERTIES AND ITS APPLICATIONS

Peptide-albumin hydrogels having a self-assembling, -dimensional nanofiber matrix are described. The nanofiber matrix comprises an amphiphilic peptide and albumin. The peptide comprises a terminal hydrophobic region, a central turning region, and a terminal hydrophilic region. Methods of making such hydrogels are also described, along with methods of using the hydrogels as scaffolding for tissue engineering, as 3-dimensional cell cultures, and for drug delivery, encapsulation of active agents (therapeutic cells, molecules, drugs, compounds), cell transplantation, cell storage, virus culture and storage. 1. A peptide-albumin hydrogel having a self-assembling , 3-dimensional nanofiber matrix , said nanofiber matrix comprising an amphiphilic peptide and albumin , wherein said peptide comprises a terminal hydrophobic region , a central turning region , and a terminal hydrophilic region.2. The peptide-albumin hydrogel of claim 1 , wherein said hydrogel is reversible.3. The peptide-albumin hydrogel of claim 2 , wherein said hydrogel has a % recovery of at least about 60% in less than about 10 minutes after destruction of said 3-dimensional nanofiber matrix by shear thinning4. The peptide-albumin hydrogel of claim 1 , wherein said hydrogel has a storage modulus of from about 50 Pa to about 10 claim 1 ,000 Pa at a pH of about 7 and a temperature of from about 20-25° C.5. The peptide-albumin hydrogel of claim 1 , wherein the weight ratio of peptide to albumin is from about 100:1 to about 1:100.6. The peptide-albumin hydrogel of claim 1 , wherein said hydrophilic region is derived from a β-spiral motif of spider flagelliform silk protein claim 1 , and said hydrophobic and turning regions are derived from the third trans-membrane segment of subunit IV in the dihydropyridine sensitive human muscle L-type calcium channel.7. The peptide-albumin hydrogel of claim 1 , further comprising an active agent encapsulated in said 3-dimensional nanofiber matrix.8. The peptide-albumin ...

Placental tissue grafts and improved methods of preparing and using the same

A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion.

THREE DIMENSIONAL SPACER FABRIC TO INCREASE THE HOLDING POWER OF SCREWS

A method of increasing a pullout force of a threaded fastener in osteoporotic bone includes drilling a hole in the bone. The spacer fabric is impregnated with a bone growth agent. A tube of the spacer fabric is sized to the hole in the bone. The tube of the spacer fabric is inserted in the hole of the bone. The spacer fabric is made from Nitinol wire. A threaded fastener is inserted into a central lumen of the tube of the spacer fabric to provide a rigid structure. The bone is grown into the spacer fabric. 1. A method of increasing a pullout force of a threaded fastener in osteoporotic bone , the method comprising:drilling a hole in the bone;sizing a tube of the spacer fabric to the hole in the bone;inserting the tube of the spacer fabric in the hole of the bone, wherein the spacer fabric is made from Nitinol wire;inserting a threaded fastener into a central lumen of the tube of the spacer fabric; andgrowing the bone into the spacer fabric.2. A method of increasing a pullout force of a threaded fastener in bone , the method comprising:drilling a hole in the bone;inserting a tube of spacer fabric in the hole of the bone; andinserting a threaded fastener into a central lumen of the tube of the spacer fabric.3. The method as recited in wherein the spacer fabric is made from a metallic wire.4. The method as recited in wherein the spacer fabric is made from Nitinol wire.5. The method as recited in including impregnating the spacer fabric with a bone growth agent.6. The method as recited in including sizing the tube of the spacer fabric to the hole in the bone.7. The method as recited in including growing the bone into the spacer fabric.8. A porous structure comprising:a structure forming a tube having a central lumen, wherein the tube is located in a hole in a bone; anda threaded fastener received in the central lumen of the tube, wherein the threaded fastener expands the structure outwardly to apply pressure against the bone, and the structure expands inwardly to apply ...

METHODS OF MAKING FIBRIN COMPOSITIONS AND ARTICLES

A method of forming a fibrin hydrogel composition including providing one or more unitary masses of a fibrin hydrogel, dividing at least one of the unitary masses of the fibrin hydrogel into a multiplicity of smaller pieces of the fibrin hydrogel, and recombining at least a portion of the smaller pieces into a cohesive mass. Dividing at least one of the unitary masses of fibrin hydrogel into a multiplicity of smaller pieces may include shearing or cutting the unitary masses to form an aqueous dispersion of the fibrin hydrogel in an aqueous medium. The aqueous dispersion of fibrin hydrogel may be applied to a substrate on a roller or an endless belt, and is optionally overlaid by a scrim. The cohesive mass of fibrin hydrogel, which may be formed by removing at least a portion of the aqueous medium from the aqueous dispersion of the smaller pieces of the fibrin hydrogel, finds uses in wound dressing articles. 1. A method of forming a fibrin hydrogel composition comprisingproviding one or more unitary masses of a fibrin hydrogel comprising fibrin;dividing at least one of the unitary masses of the fibrin hydrogel into a plurality of smaller pieces of the fibrin hydrogel;recombining at least a portion of the smaller pieces into a cohesive mass, optionally wherein the cohesive mass is on a substrate.2. The method of claim 1 , wherein dividing at least one of the unitary masses of the fibrin hydrogel into a plurality of smaller pieces of the fibrin hydrogel comprises shearing the one or more unitary masses of the fibrin hydrogel to form an aqueous dispersion of the smaller pieces of the fibrin hydrogel in an aqueous medium.3. The method of claim 2 , further comprising adding an aqueous liquid to the one or more unitary masses of the fibrin hydrogel.4. The method of claim 1 , wherein the smaller pieces of the fibrin hydrogel exhibit a particle size of no greater than 5 mm.5. The method of claim 3 , wherein the one or more unitary masses of the fibrin hydrogel comprise a ...

NANOFIBER-HYDROGEL COMPOSITES FOR CELL AND TISSUE DELIVERY

A soft tissue device can incorporate a composite material comprising a gel and at least one nanostructure disposed within the gel. A soft tissue device can further incorporate biologically active materials such as cells, tissues. A method for healing a soft tissue defect while promoting soft tissue regeneration can include applying a soft tissue device to a soft tissue defect, wherein the composite material includes a gel and a nanostructure disposed within the gel. A method for manufacturing a soft tissue device for use in healing soft tissue defects can include providing a gel, disposing nanofibers within the gel, and a biologically active material. 138-. (canceled)39. A soft tissue device , comprising:a biologically active material, anda population of substantially non-spherical microbeads comprising a functionalized hyaluronic acid network covalently linked to a plurality of polycaprolactone fibers having a mean length of less than about 200 micrometers, and a crosslinking agent present at a concentration from about 1 mg/mL to about 25 mg/mL, wherein the mean size of the non-spherical microbeads is within the range of about 50 micrometers to about 300 micrometers along the longest dimension,wherein the biologically active material comprises a population of adipose cells, autologous adipose cells, allogenic cells, genetically modified allogenic cells, stem cells, mesenchymal stem cells, genetically modified stem cells, genetically modified allogenic induced pluripotent stem (iPS) cells, genetically modified hypoimmunogenic pluripotent stem cells, adipose stromal vascular fraction, adipose tissue, autologous adipose tissue, lipoaspirate, a derivative thereof, or a combination thereof,wherein the soft tissue device is capable of being implanted or injected into a target tissue of a subject in need thereof.40. The device of claim 39 , wherein the biologically active material is operably encapsulated within the non-spherical microbeads.41. The device of claim 39 , ...

TECHNOLOGIES FOR PANCREATIC ISLET TRANSPLANTATION

Biocompatible nanomatrices composed of peptide amphiphiles are provided for the embedding of cell populations for their implantation into a recipient animal or human. To confine the nanomatrix to a site of implantation, the nanomatrix can be encapsulated in a nanofiber sack formed from an electrospun nanofiber sheet. The nanofiber sheets are porous and have surface indentations that promote the vascularization of the implant, thereby maintain the viability and biofunctions of the cells, as wells as delivering cell-product products to the circulatory system to the benefit of the recipient subject. The implants may further include cell growth factors that can be beneficial to the survival of the cells as to promote angiogenesis and infiltration of the implant by new blood vessels. 1. A biocompatible implant comprising:(i) a biocompatible nanomatrix gel comprising a plurality of a peptide amphiphile monomers cross-linked by divalent metal anions; and(ii) a biocompatible nanofiber sack, wherein said nanofiber sack is formed from a porous electrospun nanofiber sheet having crater-like surface indentations.2. The biocompatible implant according to claim 1 , wherein the peptide amphiphile monomers have the formula (CH(CH)CONH-GTAGLIGQERGDS) (SEQ ID NO.: 1).3. The biocompatible implant according to claim 1 , further comprising at least one cell growth factor claim 1 , wherein the at least one cell growth factor is incorporated in the nanomatrix gel claim 1 , is incorporated in the nanofiber sack claim 1 , or both incorporated in the nanomatrix gel and in the nanofiber sack.4. The biocompatible implant according to claim 1 , further comprising a population of isolated animal or human cells embedded in the nanomatrix gel.5. The biocompatible implant according to claim 3 , wherein the at least one cell growth factor is releasable from the biocompatible implant.6. The biocompatible implant according to claim 3 , wherein the at least one cell growth factor is an angiogenic ...

COMPOSITIONS AND METHODS FOR PROMOTING BONE FORMATION

A method for promoting bone formation is provided. More specifically, a method for promoting bone formation by promoting osteoclast formation is provided. In one embodiment, an implant comprising an implantable material and an osteoclast stimulating substance is provided. 1. An implant for promoting bone formation comprising:an implantable material; anda stimulating substance, wherein the stimulating substance stimulates osteoclast formation.2. The implant of claim 1 , wherein the material is mineralized bone.3. The implant of claim 1 , wherein the material is hydroxyapatite.4. The implant of claim 1 , wherein the material is a calcium phosphate material.5. The implant of claim 1 , further comprising a second stimulating substance claim 1 , wherein the second stimulating substance stimulates osteoblast formation or recruitment in vivo.6. The implant of claim 1 , further comprising a second stimulating substance claim 1 , wherein the second stimulating substance enhances resorbing activity of osteoclasts in vivo.7. The implant of claim 1 , wherein the stimulating substance is one of RANKL claim 1 , MCSF claim 1 , ADAM-12 claim 1 , PTH claim 1 , PTHrP claim 1 , VEGF claim 1 , hydrocortisone claim 1 , 1 claim 1 ,25 dihydroxyvitamin D3 claim 1 , PGE2 claim 1 , TNFalpha claim 1 , IL-1beta claim 1 , IL-3 claim 1 , IL-6 claim 1 , IL-11 claim 1 , and bFGF.8. The implant of claim 1 , wherein the stimulating substance is a DNA that encodes one or more of RANKL claim 1 , MCSF claim 1 , ADAM-12 claim 1 , PTH claim 1 , PTHrP claim 1 , VEGF claim 1 , hydrocortisone claim 1 , 1 claim 1 ,25 dihydroxyvitamin D3 claim 1 , PGE2 claim 1 , TNFalpha claim 1 , IL-1beta claim 1 , IL-3 claim 1 , IL-6 claim 1 , IL-11 claim 1 , and bFGF.9. The implant of claim 1 , wherein the implant is load-bearing.10. The implant of claim 1 , wherein the implantable material comprises large segmental allograft pieces.11. A method of forming an implant comprising:applying a stimulating substance that ...

COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR

Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, transdifferentiation, and proliferation of animal cells into the osteoblast blast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes. 1113. The composition of any one of - claims 1 , wherein the isolated cells capable of differentiating into bone cells are isolated human bone marrow-derived mesenchymal stem cells claims 1 , human mesenchymal stem cells of adipose tissue claims 1 , human mesenchymal stem cells of blood claims 1 , human mesenchymal stem cells of bone allograft or autograft tissues claims 1 , human mesenchymal stem cells of dental pulp claims 1 , human pericytes claims 1 , human myoblasts claims 1 , and human chondrocytes claims 1 , human osteoprogenitor cells claims 1 , urine stem cells claims 1 , or their respective progenitor cells such as stem cell isolated from amniotic fluid or cord blood claims 1 , embryonic stem cells claims 1 , and induced pluripotent stem cells.123. The composition of - wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.137. The composition of - wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.14. The composition of compound 8-10 wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.1510. The compositions of any one of - further comprising a calcium phosphate ...

OSTEOGENIC CELL DELIVERY MATRIX

Compositions and methods for augmenting bone formation by administering isolated human mesenchymal stem cells (hMSCs) within a matrix provided. By adding calcium and/or phosphate ions to the matrix, one may foster greater bone regeneration. 118-. (canceled)19. A method of treating a bone defect in which a bone defect site possesses at least one cavity , said method comprising inserting a collagen matrix into the defect , the collagen matrix comprising a plurality of ceramic particles embedded in the collagen , wherein the matrix further comprises calcium and/or phosphate ions , and stem cells , wherein the matrix allows influx of at least one progentior , bone and/or cartilage cell therein.20. A method according to claim 19 , wherein the matrix further comprises BMP.21. A method according to claim 19 , wherein the matrix has a porosity between about 50% to about 70% and comprises calcium ions claim 19 , phosphate ions and demineralized bone matrix claim 19 , the calcium ions being complexed to the phosphate ions as calcium phosphate ions claim 19 , wherein the calcium and phosphate ions are available in a quantity to have a biological effect on the stem cells claim 19 , and the calcium and phosphate ions are present in a ratio of about 1:5 to about 1:3 or about 5:1 to about 3:1.22. A method according to claim 19 , wherein the stem cells are allogenic stem cells.23. A method according to claim 19 , wherein the matrix comprises pores and at least 30% of the pores are between about 50 micrometers and about 150 micrometers. Bone is a composite material that contains impure hydroxyapatite, collagen and a variety of non-collagenous proteins, as well as embedded and adherent cells. Due to disease, a congenital defect or an accident, a person may lose or be missing part or all of one or more bones or regions of cartilage in his or her body, and/or have improper growth or formation of bone and/or cartilage.That an organism is missing part of a bone or has a defect is not ...

COMPOSITIONS AND METHODS FOR ENHANCING HEALING AND REGENERATION OF BONE AND SOFT TISSUE

The invention features biodegradable materials, and in vitro and in vivo methods of using such compositions to promote bone and soft tissue growth and healing. 1. A composition comprising:a) a biodegradable polymer; andb) a honey.2. The composition of further comprising a filler.3. The composition of any of or claim 1 , wherein the biodegradable polymer comprises a protein.43. The composition of any of through claims 1 , wherein the biodegradable polymer comprises gelatin.54. The composition of any of through claims 1 , wherein the biodegradable polymer comprises collagen.65. The composition of any of through claims 1 , wherein the biodegradable polymer comprises poly(lactic acid) claims 1 , polydioxanone (PDO) or a blend thereof with gelatin or collagen.7. The composition of claim 2 , wherein the filler comprises chitin whiskers.8. The composition of claim 2 , wherein the filler comprises hydroxyapatite.9. The composition of claim 2 , wherein the filler is present in an amount of 1-300 parts by weight relative to 100 parts by weight of the biodegradable polymer.10. The composition of claim 7 , wherein the chitin whiskers are present in an amount of about 15 parts by weight relative to 100 parts by weight of the biodegradable polymer.11. The composition of claim 7 , wherein the chitin whiskers have an average diameter of about 25-75 nm.12. The composition of claim 7 , wherein the chitin whiskers have an average diameter of about 50 nm.13. The composition of claim 7 , wherein the chitin whiskers have an average length of about 200-400 nm.14. The composition of claim 7 , wherein the chitin whiskers have an average length of about 250-300 nm.15. The composition of claim 7 , wherein the chitin whiskers have an average length of about 280 nm.16. The composition of claim 7 , wherein the chitin whiskers have an average diameter of about 3 μm or less.17. The composition of claim 7 , wherein the chitin whiskers have an average diameter of about 1 μm or less.18. The ...

Compounds and Compositions for Ossification and Methods Related Thereto

The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. 1. A method of forming bone or cartilage , comprising implanting a graft composition comprising a 2 ,4-diamino-1 ,3 ,5-triazine derivative or salt thereof in a subject under conditions such that bone or cartilage forms in the graft composition.2. The method of claim 1 , wherein the graft composition further comprises a bone morphogenetic protein.3. The method of claim 1 , wherein the subject has a void in the bony structure wherein the graft composition is implanted in the void.4. The method of claim 3 , wherein the void is in a bone selected from an extremity claim 3 , maxilla claim 3 , mandible claim 3 , pelvis claim 3 , spine and/or cranium.5. The method of claim 3 , wherein said void is a result of surgical removal of bone.6. The method of claim 1 , further comprising the step of securing movement of bone structure with a fixation system claim 1 , and removing the system after bone forms in the implanted graft.8. The method of claim 1 , wherein the 2 claim 1 ,4-diamino-1 claim 1 ,3 claim 1 ,5-triazine derivative is a compound selected from the group consisting of:1-benzyl-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(4-methoxybenzyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(3-methoxybenzyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(4-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine;1-(3-chloro-4-methoxyphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3, 5-triazine;1-(3-chloro-4-methylphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl- ...

BIOABSORBABLE POLYMERIC COMPOSITION FOR A MEDICAL DEVICE

A biodegradable and biocompatible nontoxic polymeric composition is provided which includes a base material such as a crystallizable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive. Medical devices manufactured from the composition are also provided. 1. A bioabsorbable stent comprising a crystallisable polymer composition , the polymer composition comprising: poly (L-lactide-co-Tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-ε-caprolactone) or poly (D-lactide-co-ε-caprolactone) , in the form of block copolymers or blocky random copolymers.2. The stent of claim 1 , wherein the polymer composition comprises poly (L-lactide-co-ε-caprolactone) or poly (D-lactide-co-ε-caprolactone).3. The stent of claim 1 , wherein the polymer composition claim 1 , comprises poly (L-lactide-co-ε-caprolactone).4. The stent of claim 1 , further comprising poly (L-lactide) moiety claim 1 , and/or a poly (D-lactide) moiety claim 1 , and/or poly L-lactide-co-Peg moiety claim 1 , and/or poly D-lactide-co-PEG moiety.5. The stent of claim 4 , wherein the polymer comprises poly(L-lactide) and/or poly(D-lactide).6. The stent of claim 3 , further comprising a poly (L-lactide) moiety claim 3 , and/or a poly (D-lactide) moiety and/or poly L-lactide-co-PEG moiety claim 3 , and/or poly D-lactide-co-PEG moiety.7. The stent of claim 6 , wherein the polymer comprises poly(L-lactide)8. The stent of claim 7 , wherein the polymer composition is further crystallized upon expansion of the stent.9. The stent of claim 7 , wherein the stent is balloon-expandable.10. The stent of claim 7 , wherein the stent comprises a hoop structure.11. The stent of claim 7 , further comprising at least one radiopaque marker.12. The stent of claim 7 , further including at least one pharmaceutical agent.13. The stent of claim 7 , further including a barrier layer which contains at least one pharmaceutical agent.14. The stent of claim 8 , wherein the polymer ...

TISSUE-ENGINEERED SILK ORGANS

This invention relates to a lamellae tissue layer, comprising a grooved silk fibroin substrate comprising tissue-specific cells. The silk fibroin substrates provides an excellent means of controlling and culturing cell and extracellular matrix development. A multitude of lamellae tissue layers can be used to create a tissue-engineered organ, such as a tissue-engineered cornea. The tissue-engineered organ is non-immunogenic and biocompatible. 147-. (Canceled)48. A grooved substrate comprising silk fibroin ,wherein thickness of the substrate ranges from 10 nm to 1 mm and,wherein groove width is at least 125 nm.49. The grooved substrate of claim 48 , wherein groove thickness depth is at least 100 nm.50. The grooved substrate of claim 48 , wherein the silk is selected from the group consisting of silkworm silk claim 48 , spider silk claim 48 , transgenic silk and genetically engineered silk.51. The grooved substrate of claim 48 , wherein the substrate comprises patterned diffractive optical surfaces.52. The grooved substrate of claims 48 , wherein the substrate comprises beta-sheet crystallinity claims 48 , andwherein the beta-sheet crystallinity is induced by water annealing.53. The grooved substrate of claim 48 , wherein the substrate comprises micropores claim 48 ,wherein spacing between the micropores is 50 um to 100 um and,wherein an average diameter of the micropores ranges from 100 nm to 100 um.54. The grooved substrate of claim 53 , wherein the micropores are created through the use of poly(ethylene oxide) phase separation chemistry claim 53 , laser ablation techniques claim 53 , or a combination thereof.55. The grooved substrate of claim 48 , wherein the substrate is non-immunogenic claim 48 , and biocompatible.56. The grooved substrate of claim 48 , further comprising at least one non-patterned silk film or circular patterned silk film.57. A method of preparing a grooved silk film claim 48 , the method comprising:(a) casting a solution comprising silk fibroin ...

Functionalization of plant tissues for human cell expansion

Decellularized plant tissues and the use of these plant tissues as scaffolds are disclosed herein. Particularly, decellularized plant tissues are functionalized such to allow for human cell adhesion, thereby allowing for their use as scaffolds for human cells. These scaffolds can then be used in a number of applications/markets, including as research tools for tissue engineering, regenerative medicine, and basic cellular biology.

DRUG-DELIVERING NERVE WRAP

Described herein are medical film materials that incorporate one or more neuro-regenerative drugs into a polymer film. The polymer film includes a copolymer of lactide and caprolactone. The neuro-regenerative drug includes the macrolactam immunosuppressant FK506. The film is configured such that when placed under physiological conditions, the neuro-regenerative drug is released in an extended, substantially linear fashion for a period of at least 30 days. 1. A medical film material , comprising:a polymer film comprising a copolymer of lactide and caprolactone; anda neuro-regenerative drug incorporated into the polymer film,wherein the polymer film is configured to provide substantially linear release of the neuro-regenerative drug over a period of at least 10 days when placed in a physiological environment.2. The medical film material as in claim 1 , wherein the neuro-regenerative drug comprises FK506.3. The medical film material as in claim 1 , wherein the neuro-regenerative drug comprises an immunosuppressant and/or anti-inflammatory macrolactam claim 1 , macrolactam derivative claim 1 , corticosteroid claim 1 , non-steroidal anti-inflammatory claim 1 , or combinations thereof.4. The medical film material as in claim 1 , wherein the neuro-regenerative drug has a log P within a range of about 2.0 to about 5.0.5. The medical film material as in claim 1 , wherein the neuro-regenerative drug has a water solubility (at 25° C.) of less than about 10 mg/L.6. The medical film material as in claim 1 , wherein the polymer film omits polylactic acid.7. The medical film material as in claim 1 , wherein the polymer forming the polymer film has an inherent viscosity of about 0.75 to 2.0 dl/g.8. The medical film material as claim 1 , wherein the lactide is L-lactide.9. The medical film material as in claim 1 , wherein the copolymer has a comonomer ratio (lactide to caprolactone on a molar percentage basis) that ranges from about 10:90 to about 90:10.10. The medical film material ...

Multifunctional-reinforced dressing

This invention relates to a surgical or medical dressing which comprises a supporting and reinforcing layer of elastomeric material (as polyethylene homopolymer) embedded in the composition of honey/additives, to supplement the mechanical strength, which would be fabricated as a single integral piece, intended to provide multi-functional properties in the wound environment, particularly for promote or expedite the regeneration or repair deep tissue injuries or chronic wounds such as ulcers. 1. A multifunctional -reinforced dressing suitable for promote or expedite the regeneration or repair of skin tissues COMPRISING: a reinforcing layer of flexible , inert , and removable reticulated elastomeric material (as polyethylene homopolymer) , connected entirely to the honey/additives composition , essential to achieve the desired mechanical and physical properties for its intended function.2Trigonella foenumgraecum. The multifunctional -reinforced dressing according to claim 1 , wherein the honey/additives composition COMPRISING highly purified substances claim 1 , which include in every single dressing the products and following amounts: Honey bees: 30.66 g claim 1 , aqueous extract seed from -7.34 g claim 1 , Policresulen 120 claim 1 ,478 mg and gelling agent Agar-Agar 0.522 g.3. The multifunctional-reinforced dressing according to claim 2 , COMPRISING a reinforcing layer of flexible claim 2 , inert claim 2 , and removable reticulated elastomeric material (as polyethylene homopolymer) embedded in the honey/additives composition during gel formation claim 2 , exerting a change in the appearance and physical characteristics of the dressing.4. A method for use in Human & Veterinary Medicine claim 2 , to promote or expedite the regeneration or repair of the deficient stromal connective tissue claim 2 , as well as stimulating re-epithelialization claim 2 , in a variety of injuries or disorders involving the skin tissues claim 2 , due to trauma claim 2 , diseases claim 2 , or ...

Methods And Compositions For The Treatment Of Open And Closed Wound Spinal Cord Injuries

Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes that may be used for the treatment of spinal cord injuries. In addition, other embodiments are directed to polymeric “fill-in” bandages that may be used for the treatment of spinal cord injuries. For example, an erodible, or biodegradable, form of biocompatible polymer of the present invention is fabricated for surgical implantation into the site of the spinal cord injury. 145-. (canceled)46. A method of treating a compression and/or contusion spinal cord injury in an animal comprising the steps of:(a) providing a suitably sized biodegradable and/or bioabsorbable polymeric article for implanting within a necrotic lesion of the spinal cord parenchyma tissue, wherein the polymeric article comprises a single layer scaffold; and(b) implanting the polymeric article within the lesion to bridge a gap in the spinal cord parenchymal tissue formed by said lesion wherein once implanted said polymeric article is not exposed to the environment outside the spinal cord.47. The method of claim 46 , wherein said polymeric article comprises a single layer linear aliphatic polyester scaffold.48. The method of claim 47 , wherein the linear aliphatic polyester is a polyglycolide or a co-polymer of poly(glycolide-co-lactide).49. The method of claim 46 , wherein the polymeric article degrades in vivo in 30 to 60 days.50. The method of claim 46 , wherein the polymeric article is a cylinder.51. The method of claim 46 , wherein the polymeric article is moldable.52. The method of claim 46 , wherein the polymeric article is tubular.53. The method of claim 46 , wherein the polymeric article further comprises one or more medicinal agents deposited onto ...

REGENERATION OF DISEASES INTERVERTEBRAL DISCS

A hydrogel composition for use in a method of regeneration of an intervertebral disc, or suppression of discogenic pain, in a mammal with intervertebral disc degeneration isdescribed. The hydrogel composition comprises cross-linked high molecular weight hyaluronan. The hydrogel composition is implanted in the mammal at a site of intervertebral disc degeneration. 1. A cross-linked high molecular weight hyaluronan (HA) hydrogel for use in a method of suppressing discogenic pain , in a mammal with intervertebral disc degeneration , in which the hydrogel is implanted in the mammal at a site of intervertebral disc degeneration.2. A hydrogel of in which the HA suppresses discogenic pain by the attenuation of sensory hyperinnervation.3. A hydrogel of in which the HA suppresses discogenic pain by reversal of thermal hyperalgesia or mechanical hyperalgesia.4. A hydrogel of in which in which the HA suppresses discogenic pain by the attenuation of nociception.5. A hydrogel of in which the hydrogel comprises a single gel network.6. A hydrogel of in which the hydrogel comprises 0.1 to 10% cross-linked HA by weight.7. A hydrogel of in which the hydrogel comprises 0.5 to 2% cross-linked HA by weight.8. A hydrogel of in which the hydrogel is chemically crosslinked.9. A hydrogel of in which the HA is cross-linked with PEG-amine.10. A hydrogel of in which the HA crosslinking comprises EDC/NHS or DMTMM chemistry.11. A hydrogel of in which the HA is derivatised with a moiety that imparts a net positive charge on the HA.12. A hydrogel of in which the hydrogel additionally comprises a pharmaceutically or biologically active agent.13. A hydrogel of in which the pharmaceutically or biologically active agent is selected from the group consisting of: a cell claim 8 , cell component claim 8 , polysaccharide claim 8 , protein claim 8 , peptide claim 8 , polypeptide claim 8 , antigen claim 8 , antibody (monoclonal or polyclonal) claim 8 , antibody fragment (for example an Fc region claim 8 , a ...

Polymeric biomaterials derived from monomers comprising hydroxyacids and phenol compounds and their medical uses

The present invention provides new classes of phenolic compounds derived from hydroxyacids and tyrosol or tyrosol analogues, useful as monomers for preparation of biocompatible polymers, and the biocompatible polymers prepared from these monomeric hydroxyacid-phenolic compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric hydroxyacid-phenolic compounds and biocompatible polymers.

HYDROGEL FOR TISSUE ENGINEERING AND BIOPRINTING

A composition includes a hydrogel that includes a plurality biodegradable natural polymer macromers crosslinked with a first agent and optionally a plurality of cells dispersed in the crosslinked macromers, the microgels are capable of being crosslinked with a second agent that is different than the first crosslinking agent. 133-. (canceled)34. A method of forming a construct , the method comprising;providing a composition that includes a plurality biodegradable crosslinkable natural polymer macromers and, optionally, a plurality of cells dispersed in the macromers,crosslinking the natural polymer macromers with a first crosslinking agent to form a hydrogel,printing the natural polymer macromers or the crosslinked hydrogel into a defined shape, andoptionally crosslinking the singly crosslinked hydrogel with a second crosslinking agent after printing to further stabilize the hydrogel and form the construct.35. The method of claim 34 , the natural polymer macromers crosslinked with the first crosslinking agent comprising a plurality of microgels.36. The method of claim 34 , the crosslinkable biodegradable natural polymer macromers comprising a plurality of acrylated and/or methacrylated natural polymer macromers.37. The method of claim 34 , the composition further comprising a cryopreservation agent claim 34 , the composition being cryopreserved and the cells having a substantially equivalent viability and functionality upon thawing compared to similar cells not cryopreserved.3834. The method of clam claim 34 , the hydrogel crosslinked with the first agent and/or second agent forming a solid or non-flowing structure with a defined shape.39. The method of claim 34 , wherein the natural polymer macromers or hydrogel is printed into a stabilizing bath/gel that is effective to maintain the shape of the printed natural polymer macromers or hydrogel.40. The method claim 39 , wherein the stabilizing gel is removed after crosslinking the printed natural polymer macromers or ...

FUNCTIONALIZED PEG FOR IMPLANTABLE MEDICAL DEVICES

A coating for a metal surface, the coating including poly(ethylene glycol) disposed on and covalently bonded directly to at least a portion of the metal surface, and a functional group grafted to at least a portion of the poly(ethylene glycol). The functional group is one of a bioactive functional group and an antimicrobial functional group. 1. A coating for a metal surface of an implantable medical device , the coating comprising:a poly(ethylene glycol) disposed on at least a portion of the metal surface, wherein the poly(ethylene glycol) is covalently bonded directly to the metal surface by an inorganic ether bond; anda functional group grafted to at least some of the poly(ethylene glycol), wherein the functional group is at least one of a bioactive functional group and an antimicrobial functional group.2. The coating of claim 1 , wherein the poly(ethylene glycol) covalently bonded directly to the metal surface is a monolayer.3. The coating of claim 1 , wherein the functional group is a bioactive functional group selected from the group consisting of an amino acid derivative and a peptide sequence.4. The coating of claim 3 , wherein the amino acid derivative is 3 claim 3 ,4-dihydroxyphenylalanine and the peptide sequence is arginine-glycine-aspartic acid.5. The coating of claim 1 , wherein the functional group is an antimicrobial functional group selected from the group consisting of chitosan and a silver salt.6. The coating of claim 1 , wherein an average molecular weight of the poly(ethylene glycol) is between about 200 grams per mole and about 20 claim 1 ,000 grams per mole.7. The coating of claim 1 , wherein an average molecular weight of the poly(ethylene glycol) is between about 400 grams per mole and about 4 claim 1 ,000 grams per mole.8. An implantable medical device comprising:a metal surface; and a poly(ethylene glycol) disposed on at least a portion of the metal surface, wherein the poly(ethylene glycol) is covalently bonded directly to the metal ...

METHODS OF MANUFACTURING BIOACTIVE GELS FROM EXTRACELLULAR MATRIX MATERIAL

The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction The manufacturing methods take advantage of a new recognition that bioactive gels from. ECM material can he created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels 114-. (canceled)15. A bioactive wound healing material comprising:an extracellular matrix. material (ECM) derived from the extracellular matrix of a mammal gelled at room temperature in a basic solution; and,particularized ECM in a size ranging from about 1 micron-1000 microns.16. The bioactive wound healing material of wherein said particularized ECM is in a size range of about 200-700 microns.17. The bioactive wound healing material of wherein said particularized ECM is in a size range of about 300-600 microns.18. The bioactive wound healing material of wherein said particularized ECM is in a size range of about 100 to 400 microns.19. The bioactive wound healing material of wherein said particularized ECM is in a size range of about 200 microns or about 400 microns.20. The bioactive wound healing material of further comprising bioactive components comprising one or more growth factors.212. The bioactive wound healing material of wherein said growth factor is selected from the group consisting of FCF claim 20 , FGF- claim 20 , CTGF claim 20 , VEGF and a combination thereof.22. The bioactive wound healing material of wherein the extracellular matrix material is selected from the. group consisting of submucosa claim 15 , tunica propria claim 15 , dermis claim 15 , and liver basement membrane.23. The bioactive wound healing material of wherein the bioactive material is foamed.24. The bioactive wound healing material of wherein the foam material comprises an adherent.25. The ...

MULTI-LAYER OSTEOINDUCTIVE, OSTEOGENIC, AND OSTEOCONDUCTIVE CARRIER

A spinal stabilization system for use in a vertebral column of a patient, comprising: a multi-layer osteogenic carrier device comprising: a delivery layer comprising a porous material and an osteogenic material; and a support layer in communication with the delivery layer, the support layer capable of substantially conforming to an anatomical feature in the vertebral column of the patient, wherein the support layer holds the delivery layer in proximity to the anatomical feature; at least one rod; at least one rod clip; and at least one fastener are disclosed. The multi-layer osteogenic carrier device can further comprise an adhesive layer capable of adhering the carrier to at least a portion of an anatomical feature, the adhesive layer in communication with at least a portion of the delivery layer. 1. A spinal stabilization system for use in a vertebral column of a patient , comprising: a delivery layer comprising a porous material and an osteogenic material; and', 'a support layer in communication with the delivery layer, the support layer capable of substantially conforming to an anatomical feature in the vertebral column of the patient,', 'wherein the support layer holds the delivery layer in proximity to the anatomical feature;, 'a multi-layer osteogenic carrier device comprisingat least one rod;at least one rod clip; andat least one fastener.2. The spinal stabilization system of claim 1 , wherein the rod clip comprises a first leg and a second leg.3. The spinal stabilization system of claim 2 , wherein the first and second legs are adapted to attach to the rod.4. The spinal stabilization system of claim 3 , wherein the rod clip further comprises an arm connected to the first and second legs by a stem.5. The spinal stabilization system of claim 4 , wherein the arm of the rod clip is positioned to apply pressure to the support layer of the multi-layer osteogenic carrier device to hold the multi-layer osteogenic carrier device in proximity to the anatomical ...

CELL MICROSHEET, SYRINGE CONTAINING THE CELL MICROSHEET, AND PRODUCTION AND USE OF THE CELL MICROSHEET

Cell microsheets are formed from a culture of cells. The cell microsheets has a size that can pass through an injection needle with a certain thickness. The cell microsheets can be produced on a surface of a cell cultureware. A stimulus-responsive polymer is immobilized on the surface having small divisions of the cell cultureware. The cell microsheets are suitable for minimally invasive treatment. 1. A cell microsheet that is formed from a culture of cells and is capable of passing through an injection needle.2. The cell microsheet set forth in claim 1 , wherein the injection needle is an 18G or thinner injection needle.3. The cell microsheet set forth in claim 1 , having an area of 20 mmor less.4. The cell microsheet set forth in claim 1 , wherein the cell microsheet is usable for cartilage tissue repair.5. The cell microsheet set forth in claim 1 , wherein the cells are derived from cartilage tissue.6. The cell microsheet set forth in claim 5 , where the cartilage tissue is of an animal with polydactyly.7. The cell microsheet set forth in claim 1 , wherein the cells are derived from stem cells.8. The cell microsheet set forth in claim 7 , wherein the stem cells include pluripotent stem cells claim 7 , embryonic stem cells claim 7 , or somatic stem cells.9. The cell microsheet set forth in claim 7 , wherein the stem cells comprise iPS cells.10. A syringe containing the cell microsheet set forth in .11. A method of producing cell microsheets formed from a culture of cells claim 1 , comprising cultivating the cells on a surface of a cell cultureware to yield the cell microsheets claim 1 , a stimulus-responsive polymer being immobilized on the surface of the cell cultureware claim 1 , the surface having small divisions.12. The method set forth in claim 11 , wherein the small divisions each have an area of 20 mmor less.13. A method of administering the cell microsheet set forth in to an animal by injection. The present invention relates to a cell microsheet, a syringe ...

INJECTABLE IN SITU POLYMERIZABLE COLLAGEN COMPOSITION

The present invention is directed to injectable acid soluble collagen compositions comprising a neutralized solution of an acid soluble collagen, EDTA and preferably a polyol, wherein the composition is injectable at physiological pH and the acid soluble collagen polymerizes upon exposure to tissue. The invention is suitable for use in soft tissue augmentation, promoting soft tissue regeneration and coating medical implants and devices. 1. A method for augmenting soft tissue , comprising ,injecting into a soft tissue deficiency a neutralized solution comprising EDTA and an acid soluble collagen selected from the group consisting of Type 1 collagen, Type III collagen and combinations thereof;wherein said acid soluble collagen undergoes fibrillogenesis upon exposure to the soft tissue to form an opaque collagen fibril matrix.2. The method of claim 1 , wherein said soft tissue deficiency is selected from the group consisting of wrinkles claim 1 , dermal folds claim 1 , dermal laxity claim 1 , skin contour defects claim 1 , dermal fine lines claim 1 , dermal furrows and dermal unevenness.3. The method of claim 1 , wherein said injection is into the soft tissue deficiency in lips or facial skin.4. The method of claim 1 , wherein said acid soluble collagen forms a collagen fibril matrix after exposure to the tissue and the matrix remains durable for at least 4 weeks after said injection.5. The method of claim 4 , wherein said matrix remains durable for at least 12 weeks after said injection.6. The method of claim 5 , wherein said matrix remains durable for at least 6 months.7. The method of claim 1 , wherein said injected composition produces regeneration of the tissue.8. The method of claim 1 , wherein said injected composition integrates with matrices of the tissue.9. The method of claim 1 , wherein said acid soluble composition forms a collagen fibril matrix that fills the soft tissue deficiency.10. The method of claim 1 , wherein said composition comprises said acid ...

METHODS FOR DEVELOPMENT AND USE OF MINIMALLY POLARIZED FUNCTION CELL MICRO-AGGREGATE UNITS IN TISSUE APPLICATIONS USING LGR4, LGR5 AND LGR6 EXPRESSING EPITHELIAL STEM CELLS

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application. 1. A method of producing a composition , comprising:a) separating fat and hypodermal elements from dermal and epidermal compartments of a mammalian tissue specimen to provide a partially processed mammalian tissue specimen; andb) separating remaining cutaneous elements of the partially processed tissue specimen, to provide the composition, wherein the composition comprises a micro-aggregate comprising at least a portion of a follicular bulge and LGR-expressing stem cells, andwherein the composition is capable of assembling functional tissue.2. The method of claim 1 , further comprising adding the composition to a delivery substrate.3. The method of claim 2 , wherein the delivery substrate is selected from scaffolding claim 2 , matrix claim 2 , particle claim 2 , cells claim 2 , fiber claim 2 , or combinations thereof.4. The method of claim 1 , further comprising adding enhancing factors or analytes to the composition.5. The method of claim 2 , further comprising adding enhancing factors or analytes to the composition.6. The method of claim 1 , further comprising applying the composition to a select target.7. The method of claim 2 , further comprising applying the composition to a select target.8. The method of claim 6 , wherein the select target is selected from a tissue region claim 6 , a wound claim 6 , a void claim 6 , a defect tissue claim 6 , or combinations thereof.9. The method claim 7 , wherein the select target is selected from ...

MULTIPOTENT POSTNATAL STEM CELLS FROM HUMAN PERIODONTAL LIGAMENT AND USES THEREOF

The invention generally relates to postnatal periodontal ligament stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal periodontal ligament multipotent stem cells, use of the cells to generate periodontium, differentiation of the cells and methods of tissue cryopreservation. 1. A method for treating trauma in a subject , comprisingadministering to the subject an effective amount of a composition comprising an effective amount of an isolated clonal population of periodontal ligament multipotent mammalian stem cells wherein the clonal population consists of human multipotent stem cells that proliferate, express STRO-1 and MUC 18, form colonies in vitro, and differentiate into periodontal ligament cells that produce collagen fibers and cementum in vivo, wherein the periodontal ligament multipotent stem cells were expanded ex vivo,thereby treating the trauma in the subject.2. The method of claim 1 , wherein the trauma is a physical injury.3. The method of claim 2 , wherein the physical injury is from an accident.4. The method of claim 2 , wherein the physical injury is from a dental procedure or a medical treatment.5. The method of claim 1 , wherein the trauma is from periodontal disease.6. The method of claim 5 , wherein the periodontal disease is periodontitis.7. The method of claim 5 , wherein the periodontal disease is gingivitis.8. The method of claim 1 , wherein the composition further comprises a biocompatible three dimensional carrier.9. The method of claim 8 , wherein the biocompatible three dimensional carrier comprises a polymer claim 8 , gelatin claim 8 , polyvinyl sponges claim 8 , a collagen matrix claim 8 , or a combination of hydroxyapatite and tricalcium phosphate.10. The method of claim 1 , wherein the periodontal ligament multipotent stem cells are transfected with a preselected nucleic acid segment and wherein the preselected nucleic acid segment encodes a hormone claim 1 , a chemokine claim 1 , a ...

Mesenchymal Stem Cell-Hydrogel-Biodegradable or Mesenchymal Stem Cell-Hydrogel-Undegradable Support Composition for Skin Regeneration or Wound Healing

The present invention relates to a composition comprising mesenchymal stem cell-hydrogel-biodegradable support or mesenchymal stem cell-hydrogel-undegradable support, a sheet comprising the composition and a method for the preparation thereof. By using the sheet comprising the adipose-derived mesenchymal stem cell-hydrogel biodegradable or undegradable support, stem cells of high activity may be applied directly to the wound without isolation process using protease. The sheet has extracellular matrices such as collagen, laminin, fibronectin and elastin secreted by stem cells in the culture stage and included completely in the hydrogel, and therefore it has superior skin regeneration and wound healing effects compared with conventional pharmaceutical preparations and shortens therapeutic period.

BIORESORBABLE TISSUE REPAIR COMPOSITION

Compositions including hyaluronic acid or derivative thereof, a borate containing crosslinking agent, a di or polyvalent metal ion, and, optionally, one or more of N-hydroxysuccinimide, and/or a cationic monomer, oligomer, or polymer selected from the group consisting of hydroxylysine, poly(N-methylethylamine), ε-poly-lysine, or polyamine, or a combination thereof are described. Also, methods for making a bioresorbable tissue repair composition and methods of correcting, sealing, connecting or repairing tissue by contacting the tissue with the bioresorbable tissue repair composition are described. 1. A composition comprising: (1) hyaluronic acid or derivative thereof , (2) a borate containing crosslinking agent , (3) a di or polyvalent metal ion , and (4) optionally one or more of N-hydroxysuccinimide , a cationic monomer , oligomer , or polymer selected from the group consisting of hydroxylysine , poly(N-methylethylamine) , ε-poly-lysine , or polyamine , or a combination thereof.2. The composition of claim 1 , wherein the crosslinking agent is one or more of boric acid claim 1 , sodium borate claim 1 , sodium tetraborate claim 1 , disodium tetraborate claim 1 , sodium tetraborate decahydrate claim 1 , anhydrous borax (NaBO) claim 1 , borax pentahydrate (NaBO.5HO) claim 1 , borax decahydrate (NaBO.10HO) claim 1 , sodium borohydride claim 1 , tributyl borate claim 1 , triethanolamine borate claim 1 , tris(trimethylsilyl)borate claim 1 , tris-borate-EDTA buffer claim 1 , triethyl borate claim 1 , triisopropyl borate claim 1 , trimethyl borate or an organoborate.3. The composition of claim 1 , wherein the monomer claim 1 , oligomer claim 1 , or polymer is ε-poly-lysine.4. The composition of claim 1 , wherein the monomer claim 1 , oligomer claim 1 , or polymer is polyethylenimine.5. The composition of claim 1 , wherein the monomer claim 1 , oligomer claim 1 , or polymer is diethylenetriamine.6. The composition of claim 1 , wherein the monomer claim 1 , oligomer claim 1 ...

POLYMER BASED HYDROGEL

The present invention relates to an anti-aging antimicrobial wound healing polymer based hydrogel. In the study of the present invention, a wound healing gel formulation is developed by combining poloxamer polymers and boron component at adequate concentrations in a carbopol based gel. The said gel exhibits fast action on the damaged area and prevents scar formation. 1. A hydrogel which is anti-aging , wound-healing and antimicrobial , comprising: a boron derivative a poloxamer and a gel; wherein the boron derivative and the poloxamer are added to the gel that is prepared as a carrier.2. The hydrogel according to claim 1 , wherein the gel comprises 1% carbopol.3. The hydrogel according to claim 3 , wherein the boron derivative is a sodium pentaborate pentahydrate-.4. The hydrogel according to claim 3 , wherein the hydrogel comprises 3% sodium pentaborate pentahydrate.5. The hydrogel according to claim 1 , wherein the hydrogel comprises 4% poloxamer.6. The hydrogel according to claim 1 , wherein a mixture of the gel claim 1 , the boron derivative and the poloxamer is stored at 4° C. for 16-24 hours.7. The hydrogel according to claim 1 , wherein the boron derivative is a boric acid.8. The hydrogel according to claim 1 , wherein the boron derivative is alkaline metal borates.9. The hydrogel according to claim 1 , wherein the boron derivative is alkaline earth metal borates.10. The hydrogel according to claim 1 , wherein the form of the hydrogel is selected from a group consisting of: lotion claim 1 , cream claim 1 , emulsion claim 1 , spray claim 1 , foam claim 1 , gelatin claim 1 , paste claim 1 , powder claim 1 , plaster claim 1 , skin plate claim 1 , wound dressing textile product. The present invention relates to an anti-aging antimicrobial wound healing polymer based hydrogelThe basic function of the skin is to create a barrier which can protect the body against environmental damages and effects, and to ensure homeostasis. Thus, any deformation that may occur in ...

Implants having a drug load of an oxysterol and methods of use

Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth. The compression resistant implant comprises a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and a freeze-dried oxysterol in an amount of about 5 wt % to about 90 wt % of the implant. Methods of making and use are further provided.

Catheter Injectable Cyclic Peptide Pro-Gelators for Myocardial Tissue Engineering

Cyclic peptide pro-gelator compositions, and methods of therapeutic use, which assemble into macromolecular hydrogel when administered through cleavage by endogenous enzymes upregulated at a site of tissue injury, such as a myocardial infarction. 1. A tissue scaffolding composition comprising a pharmaceutically acceptable carrier and a cyclic peptide having a substrate recognition sequence that when enzymatically cleaved linearizes and self-assembles with like-kind peptides into a hydrogel.2. The composition of claim 1 , wherein the cyclic peptide is disulfide bonded by terminal cysteine residues and comprises repeating amino acid sequence KFDF (SEQ ID NO:1) and wherein the peptide self-assembles into a hydrogel via beta-sheets.3. The composition of claim 1 , wherein the substrate recognition sequence is specific for inflammatory-related enzymes claim 1 , matrix metalloproteinases (MMP)-2/9 and/or elastase.4. The composition of claim 1 , wherein therapeutic peptide comprises a MMP-2/9 cleavable substrate recognition amino acid sequence PLGLAG (SEQ ID NO:2).5. The composition of claim 1 , wherein the peptide is labeled for detection.6. The composition of claim 1 , wherein the composition further comprises a therapeutic agent claim 1 , a chemotactic agent claim 1 , an antibiotic claim 1 , or a growth factor.7. The composition of claim 1 , wherein the peptide comprises the amino acid sequence CKFDFKFDFKFDFPLGLAGC (SEQ ID NO:7).8. A method of creating a scaffold for tissue repair in a patient in need thereof comprising administering to the patient a cyclic peptide having a substrate recognition sequence that when enzymatically cleaved linearizes and self-assembles with like-kind peptides into a hydrogel.9. The method of claim 8 , wherein the cyclic peptide has a disulfide bonded by terminal cysteine residues and comprises repeating amino acid sequence KFDF (SEQ ID NO:1) and wherein the peptide self-assembles into a hydrogel via beta-sheets.10. The method of claim 8 , ...

Coating and Coating Method

The present invention discloses a coating for a medical implant, wherein at least a part of said coating contains an osseointegration agent and the same and/or a different part of the coating contains an antimicrobial metal agent. 151-. (canceled)52. A medical implant comprising an implant surface having a surface coating comprising an osseointegration agent , and an antimicrobial metal agent present in discrete particles and at a concentration sufficient to have an anti-bacterial effect.53. The medical implant of claim 52 , wherein the antimicrobial metal agent in the surface coating is present at about 0.1 to about 10 weight percent.54. The medical implant of claim 52 , wherein in the antimicrobial metal agent is silver claim 52 , copper claim 52 , or zinc.55. The medical implant of claim 54 , wherein an osseointegration agent is substituted with one or more of the antimicrobial metal agents silver claim 54 , copper claim 54 , or zinc.56. The medical implant of claim 52 , wherein the discrete particles of an antimicrobial metal agent are particles of metallic silver or a silver compound.57. The medical implant of claim 52 , wherein the discrete particles are discrete metallic silver particles.58. The medical implant of claim 57 , wherein an osseointegration agent is silver-substituted.59. The medical implant of claim 57 , wherein the metallic silver particles are spherical or irregular in shape.60. The medical implant of claim 59 , wherein the diameter of the metallic silver particles is about 15 nm to about 10 μm.61. The medical implant of claim 52 , wherein an osseointegration agent is substituted with an antimicrobial metal agent.62. The medical implant of claim 52 , wherein the antimicrobial metal agent is silver.63. The medical implant of claim 52 , wherein an osseointegration agent is silver-substituted.64. The medical implant of claim 63 , wherein the silver concentration from the silver-substituted osseointegration agent is substantially homogeneous ...

DUAL MATERIAL IMPLANT

The present invention generally relates to an orthopedic implant. Specifically, the present invention relates to an implant that incorporates a purposefully designed material that optimizes bony ingrowth combined with a support material configured to provide structural integrity. 1. An orthopedic implant comprising:a porous section comprising a first implant material for the promotion of bony ingrowth; anda support section comprising a second implant material for structural support configured to substantially retain the porous section.2. The orthopedic implant of claim 1 , wherein the first implant material is tri-Calcium Phosphate claim 1 , Hydroxy-Apatite claim 1 , poly(methyl methacrylate) or a combination of the foregoing materials.3. The orthopedic implant of claim 1 , wherein the second implant material is PEEK claim 1 , PEEK-HA claim 1 , Carbon reinforced PEEK claim 1 , poly(methyl methacrylate) or a combination of the foregoing materials.4. An orthopedic implant comprising:a porous section formed of a first implant material and comprising a three-dimensional matrix configured as a network of selectively interconnected nonuniform channels forming a nonuniform web consisting of a plurality of intersections that provide a porous region of varying porosity within the implant for bony ingrowth; anda support section configured to substantially retain the porous section to provide structural support for the implant, the support section comprising one or more hollow recesses adapted as openings which enable contact between the first material of the porous section and bone after the implant is implanted.5. The orthopedic implant of claim 4 , wherein the first implant material is tri-Calcium Phosphate.6. The orthopedic implant of claim 4 , wherein the first implant material is Hydroxy-Apatite.7. The orthopedic implant of claim 4 , wherein the first implant material is poly(methyl methacrylate).8. The orthopedic implant of claim 4 , wherein the second implant material ...

PREFABRICATED ALGINATE-DRUG BANDAGES

The invention provides a solution to the drawbacks associated with conventional alginate dressings. This invention features improved alginate dressings or bandages as well as a fabrication process that results in an alginate sheet that is preloaded with drug, can be stored in a freeze-dried state, and is compliant and ready to use at the time of administration. 1. A composition comprising a cryo-organized , crosslinked alginate structure comprising a therapeutic agent , wherein said structure comprises a Young's modulus of 50 to 500 kiloPascals at room temperature.2. A composition comprising a cryo-organized , crosslinked alginate structure comprising a therapeutic agent , wherein said composition further comprises a gauze fabric , and wherein said structure comprises a Young's modulus of 100 to 10 ,000 kiloPascals at room temperature.3. The composition of claim 1 , wherein said cryo-organized structure comprises a network of interconnected crosslinked pores.4. The composition of claim 1 , wherein said therapeutic agent comprises substance P.5. A method of promoting wound healing or tissue repair claim 1 , comprising contacting a bodily tissue of a subject with the composition of .6. The method of claim 5 , wherein said therapeutic agent comprises substance P.7. The method of claim 5 , wherein the size of a wound of the subject is reduced compared to the size of the wound of the subject prior to the contacting step.8. The method of claim 7 , wherein the size of the wound is reduced by at least 1.5-fold.9. The method of claim 7 , wherein a complete closure of a wound in the subject occurs following said contacting step.10. (canceled)11. The method of claim 7 , wherein the wound is a diabetic wound.12. The method of claim 11 , wherein the diabetic wound comprises an ischemic wound claim 11 , optionally wherein the ischemic wound comprises a neuroischemic wound.13. A method of making a compliant bandage composition claim 11 , comprising providing an alginate solution ...

METHOD FOR PREPARING PARTICULATE DECELLULARIZED TISSUE

A particulate decellularized tissue is provided which shows sufficiently effective tissue regeneration and does not show cytotoxicity when used as material for cell culture. In accordance with the method for preparing a particulate decellularized tissue comprising a step of applying a high hydrostatic pressure to animal-derived tissues in a medium, a particulate decellularized tissue is obtained which does not show cytotoxicity but shows the effect of cellular attraction and the effect of induction of cellular differentiation and shows a high effect of tissue regeneration. 1. A method for preparing a particulate decellularized tissue comprising a step of applying a high hydrostatic pressure to animal-derived tissues in a medium.2. The method for preparing a particulate decellularized tissue according to wherein said high hydrostatic pressure is 2 to 1 claim 1 ,500 MPa.3. The method for preparing a particulate decellularized tissue according to wherein said high hydrostatic pressure is applied after the animal-derived tissues are pulverized.4. The method for preparing a particulate decellularized tissue according to wherein animal-derived decellularized tissues obtained by applying a high hydrostatic pressure to the animal-derived tissues in a medium are pulverized.5. The method for preparing a particulate decellularized tissue according to wherein animal-derived decellularized tissues obtained by applying a high hydrostatic pressure to the animal-derived tissues in a medium are washed with a washing liquid not comprising an anionic surfactant and/or a nonionic surfactant.6. A particulate decellularized tissue prepared by the method for preparing a particulate decellularized tissue according to .7. A material for transplant or treatment using the particulate decellularized tissue according to .8. A material for cell culture using the particulate decellularized tissue according to . The present invention relates to a method for preparing a particulate decellularized ...